0001861657 2026-01-01 2026-06-30 0001861657 2026-08-13 0001861657 2026-06-30 0001861657 2025-12-31 0001861657 2026-04-01 2026-06-30 0001861657 2025-04-01 2025-06-30 0001861657 2025-01-01 2025-06-30 0001861657 CNTN:NetworkValidationRevenueMember 2026-04-01 2026-06-30 0001861657 CNTN:NetworkValidationRevenueMember 2025-04-01 2025-06-30 0001861657 CNTN:NetworkValidationRevenueMember 2026-01-01 2026-06-30 0001861657 CNTN:NetworkValidationRevenueMember 2025-01-01 2025-06-30 0001861657 CNTN:OtherRevenueMember 2026-04-01 2026-06-30 0001861657 CNTN:OtherRevenueMember 2025-04-01 2025-06-30 0001861657 CNTN:OtherRevenueMember 2026-01-01 2026-06-30 0001861657 CNTN:OtherRevenueMember 2025-01-01 2025-06-30 0001861657 us-gaap:CommonStockMember 2025-03-31 0001861657 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001861657 us-gaap:RetainedEarningsMember 2025-03-31 0001861657 us-gaap:TreasuryStockCommonMember 2025-03-31 0001861657 2025-03-31 0001861657 us-gaap:CommonStockMember 2024-12-31 0001861657 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001861657 us-gaap:RetainedEarningsMember 2024-12-31 0001861657 us-gaap:TreasuryStockCommonMember 2024-12-31 0001861657 2024-12-31 0001861657 us-gaap:CommonStockMember 2026-03-31 0001861657 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001861657 us-gaap:RetainedEarningsMember 2026-03-31 0001861657 us-gaap:TreasuryStockCommonMember 2026-03-31 0001861657 2026-03-31 0001861657 us-gaap:CommonStockMember 2025-12-31 0001861657 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001861657 us-gaap:RetainedEarningsMember 2025-12-31 0001861657 us-gaap:TreasuryStockCommonMember 2025-12-31 0001861657 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0001861657 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0001861657 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001861657 us-gaap:TreasuryStockCommonMember 2025-04-01 2025-06-30 0001861657 us-gaap:CommonStockMember 2025-01-01 2025-06-30 0001861657 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-06-30 0001861657 us-gaap:RetainedEarningsMember 2025-01-01 2025-06-30 0001861657 us-gaap:TreasuryStockCommonMember 2025-01-01 2025-06-30 0001861657 us-gaap:CommonStockMember 2026-04-01 2026-06-30 0001861657 us-gaap:AdditionalPaidInCapitalMember 2026-04-01 2026-06-30 0001861657 us-gaap:RetainedEarningsMember 2026-04-01 2026-06-30 0001861657 us-gaap:TreasuryStockCommonMember 2026-04-01 2026-06-30 0001861657 us-gaap:CommonStockMember 2026-01-01 2026-06-30 0001861657 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-06-30 0001861657 us-gaap:RetainedEarningsMember 2026-01-01 2026-06-30 0001861657 us-gaap:TreasuryStockCommonMember 2026-01-01 2026-06-30 0001861657 us-gaap:CommonStockMember 2025-06-30 0001861657 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001861657 us-gaap:RetainedEarningsMember 2025-06-30 0001861657 us-gaap:TreasuryStockCommonMember 2025-06-30 0001861657 2025-06-30 0001861657 us-gaap:CommonStockMember 2026-06-30 0001861657 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0001861657 us-gaap:RetainedEarningsMember 2026-06-30 0001861657 us-gaap:TreasuryStockCommonMember 2026-06-30 0001861657 us-gaap:PrivatePlacementMember 2025-04-01 2025-06-30 0001861657 CNTN:AtTheMarketOfferingsMember 2025-04-01 2025-06-30 0001861657 us-gaap:PrivatePlacementMember 2025-01-01 2025-06-30 0001861657 CNTN:AtTheMarketOfferingsMember 2025-01-01 2025-06-30 0001861657 CNTN:AtTheMarketOfferingsMember 2026-04-01 2026-06-30 0001861657 us-gaap:IPOMember 2026-01-01 2026-06-30 0001861657 CNTN:AtTheMarketOfferingsMember 2026-01-01 2026-06-30 0001861657 us-gaap:EmployeeStockOptionMember 2026-01-01 2026-06-30 0001861657 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-06-30 0001861657 us-gaap:WarrantMember 2026-01-01 2026-06-30 0001861657 us-gaap:WarrantMember 2025-01-01 2025-06-30 0001861657 CNTN:CashSecuritiesPurchaseAgreementsMember 2025-11-03 2025-11-03 0001861657 CNTN:PrefundedWarrantsMember CNTN:CashSecuritiesPurchaseAgreementsMember 2025-11-03 0001861657 CNTN:CashSecuritiesPurchaseAgreementsMember 2025-11-03 0001861657 CNTN:PrefundedWarrantsMember CNTN:CryptocurrencyOfferingMember 2025-11-03 0001861657 CNTN:PrefundedWarrantsMember CNTN:CryptocurrencyOfferingMember 2025-11-03 2025-11-03 0001861657 CNTN:CashOfferingAndCryptocurrencyOfferingMember 2025-11-03 2025-11-03 0001861657 CNTN:CashOfferingAndCryptocurrencyOfferingMember 2025-11-03 2026-11-03 0001861657 CNTN:StrategicAdvisorWarrantsMember CNTN:CashSecuritiesPurchaseAgreementsAndCrytocurrencySecuritiesPurchaseAgreementsMember 2025-11-03 0001861657 srt:MaximumMember CNTN:AtMarketEquityOfferingsMember CNTN:TwoThousandTwentyFiveATMAgreementMember 2025-11-06 2025-11-06 0001861657 CNTN:TwoThousandTwentyFiveATMAgreementMember 2025-01-01 2025-12-31 0001861657 CNTN:TwoThousandTwentyFiveATMAgreementMember 2025-12-31 0001861657 us-gaap:CommonStockMember 2026-01-21 2026-01-21 0001861657 us-gaap:CommonStockMember 2026-01-21 0001861657 CNTN:PrefundedWarrantsMember 2026-01-21 0001861657 2026-01-21 0001861657 2026-01-21 2026-01-21 0001861657 CNTN:AtMarketEquityOfferingsMember CNTN:MarchTwoThousandTwentySixATMAgreementMember 2026-03-03 2026-03-03 0001861657 CNTN:TwoThousandTwentyFiveATMAgreementMember 2026-01-01 2026-06-30 0001861657 CNTN:TwoThousandSeventeenStockIncentivePlanMember 2026-06-30 0001861657 CNTN:TwoThousandSeventeenStockIncentivePlanMember 2026-01-01 2026-06-30 0001861657 CNTN:TwoThousandSeventeenStockIncentivePlanMember 2025-12-31 0001861657 CNTN:TwoThousandNineteenStockIncentivePlanMember 2026-01-01 2026-06-30 0001861657 CNTN:TwoThousandNineteenStockIncentivePlanMember 2026-06-30 0001861657 CNTN:TwoThousandNineteenStockIncentivePlanMember 2025-12-31 0001861657 CNTN:TwoThousandTwentyThreeOmnibusEquityIncentivePlanMember 2025-01-01 2025-01-01 0001861657 CNTN:TwoThousandTwentyThreeOmnibusEquityIncentivePlanMember 2025-06-10 2025-06-10 0001861657 CNTN:TwoThousandTwentyThreeOmnibusEquityIncentivePlanMember 2025-10-09 2025-10-09 0001861657 CNTN:TwoThousandTwentyThreeOmnibusEquityIncentivePlanMember 2025-10-09 0001861657 CNTN:TwoThousandTwentyThreeOmnibusEquityIncentivePlanMember 2026-01-29 2026-01-29 0001861657 CNTN:TwoThousandTwentyThreeOmnibusEquityIncentivePlanMember 2026-01-30 2026-01-30 0001861657 CNTN:TwoThousandTwentyThreeOmnibusEquityIncentivePlanMember 2026-01-01 2026-06-30 0001861657 CNTN:TwoThousandTwentyThreeOmnibusEquityIncentivePlanMember 2025-01-01 2025-12-31 0001861657 CNTN:TwoThousandTwentyThreeOmnibusEquityIncentivePlanMember 2025-01-01 2025-06-30 0001861657 CNTN:TwoThousandTwentyThreeOmnibusEquityIncentivePlanMember 2026-06-30 0001861657 CNTN:StrategicAdvisorWarrantsMember 2026-01-01 2026-06-30 0001861657 CNTN:StrategicAdvisorWarrantsMember 2026-06-30 0001861657 us-gaap:RestrictedStockUnitsRSUMember 2025-01-01 2025-06-30 0001861657 us-gaap:RestrictedStockUnitsRSUMember 2026-01-01 2026-06-30 0001861657 us-gaap:RestrictedStockUnitsRSUMember 2026-04-01 2026-06-30 0001861657 us-gaap:RestrictedStockUnitsRSUMember 2025-04-01 2025-06-30 0001861657 us-gaap:RestrictedStockUnitsRSUMember 2026-06-30 0001861657 2025-01-01 2025-12-31 0001861657 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-06-30 0001861657 us-gaap:EmployeeStockOptionMember 2025-06-30 0001861657 us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax us-gaap:SegmentDiscontinuedOperationsMember 2026-04-01 2026-06-30 0001861657 us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax us-gaap:SegmentDiscontinuedOperationsMember 2025-04-01 2025-06-30 0001861657 us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax us-gaap:SegmentDiscontinuedOperationsMember 2026-01-01 2026-06-30 0001861657 us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax us-gaap:SegmentDiscontinuedOperationsMember 2025-01-01 2025-06-30 0001861657 us-gaap:GeneralAndAdministrativeExpense 2026-04-01 2026-06-30 0001861657 us-gaap:GeneralAndAdministrativeExpense 2025-04-01 2025-06-30 0001861657 us-gaap:GeneralAndAdministrativeExpense 2026-01-01 2026-06-30 0001861657 us-gaap:GeneralAndAdministrativeExpense 2025-01-01 2025-06-30 0001861657 us-gaap:ShareBasedCompensation 2026-04-01 2026-06-30 0001861657 us-gaap:ShareBasedCompensation 2025-04-01 2025-06-30 0001861657 us-gaap:ShareBasedCompensation 2026-01-01 2026-06-30 0001861657 us-gaap:ShareBasedCompensation 2025-01-01 2025-06-30 0001861657 CNTN:WarrantsOneMember 2026-01-01 2026-06-30 0001861657 CNTN:WarrantsOneMember 2026-06-30 0001861657 CNTN:WarrantsTwoMember 2026-01-01 2026-06-30 0001861657 CNTN:WarrantsTwoMember 2026-06-30 0001861657 CNTN:WarrantsThreeMember 2026-01-01 2026-06-30 0001861657 CNTN:WarrantsThreeMember 2026-06-30 0001861657 CNTN:WarrantsFourMember 2026-01-01 2026-06-30 0001861657 CNTN:WarrantsFourMember 2026-06-30 0001861657 CNTN:WarrantsFiveMember 2026-01-01 2026-06-30 0001861657 CNTN:WarrantsFiveMember 2026-06-30 0001861657 CNTN:WarrantsSixMember 2026-01-01 2026-06-30 0001861657 CNTN:WarrantsSixMember 2026-06-30 0001861657 CNTN:WarrantsSevenMember 2026-01-01 2026-06-30 0001861657 CNTN:WarrantsSevenMember 2026-06-30 0001861657 CNTN:WarrantsEightMember 2026-01-01 2026-06-30 0001861657 CNTN:WarrantsEightMember 2026-06-30 0001861657 CNTN:WarrantsNineMember 2026-01-01 2026-06-30 0001861657 CNTN:WarrantsNineMember 2026-06-30 0001861657 CNTN:WarrantsTenMember 2026-01-01 2026-06-30 0001861657 CNTN:WarrantsTenMember 2026-06-30 0001861657 CNTN:WarrantsElevenMember 2026-01-01 2026-06-30 0001861657 CNTN:WarrantsElevenMember 2026-06-30 0001861657 CNTN:WarrantsTwelveMember 2026-01-01 2026-06-30 0001861657 CNTN:WarrantsTwelveMember 2026-06-30 0001861657 CNTN:WarrantsThirteenMember 2026-01-01 2026-06-30 0001861657 CNTN:WarrantsThirteenMember 2026-06-30 0001861657 CNTN:WarrantsFourteenMember 2026-01-01 2026-06-30 0001861657 CNTN:WarrantsFourteenMember 2026-06-30 0001861657 CNTN:WarrantsFifteenMember 2026-01-01 2026-06-30 0001861657 CNTN:WarrantsFifteenMember 2026-06-30 0001861657 CNTN:WarrantsSixteenMember 2026-01-01 2026-06-30 0001861657 CNTN:WarrantsSixteenMember 2026-06-30 0001861657 CNTN:WarrantsSeventeenMember 2026-01-01 2026-06-30 0001861657 CNTN:WarrantsSeventeenMember 2026-06-30 0001861657 CNTN:WarrantsEighteenMember 2026-01-01 2026-06-30 0001861657 CNTN:WarrantsEighteenMember 2026-06-30 0001861657 CNTN:WarrantsNineteenMember 2026-01-01 2026-06-30 0001861657 CNTN:WarrantsNineteenMember 2026-06-30 0001861657 CNTN:WarrantsTwentyMember 2026-01-01 2026-06-30 0001861657 CNTN:WarrantsTwentyMember 2026-06-30 0001861657 CNTN:WarrantsTwentyOneMember 2026-01-01 2026-06-30 0001861657 CNTN:WarrantsTwentyOneMember 2026-06-30 0001861657 CNTN:WarrantsTwentyTwoMember 2026-01-01 2026-06-30 0001861657 CNTN:WarrantsTwentyTwoMember 2026-06-30 0001861657 CNTN:WarrantsTwentyThreeMember 2026-01-01 2026-06-30 0001861657 CNTN:WarrantsTwentyThreeMember 2026-06-30 0001861657 CNTN:WarrantsTwentyFourMember 2026-01-01 2026-06-30 0001861657 CNTN:WarrantsTwentyFourMember 2026-06-30 0001861657 2023-01-01 2023-01-31 0001861657 CNTN:MinotaurAgreementMember 2026-04-01 2026-06-30 0001861657 CNTN:MinotaurAgreementMember 2026-01-01 2026-06-30 0001861657 CNTN:MinotaurAgreementMember 2025-04-01 2025-06-30 0001861657 CNTN:MinotaurAgreementMember 2025-01-01 2025-06-30 0001861657 CNTN:AppliedBiomedicalScienceInstituteMember 2023-07-27 2023-07-27 0001861657 CNTN:ABSIMember 2023-07-04 2023-07-05 0001861657 srt:MaximumMember CNTN:AppliedBiomedicalScienceInstituteMember 2023-07-04 2023-07-05 0001861657 2024-03-11 2024-03-11 0001861657 CNTN:AppliedBiomedicalScienceInstituteMember 2026-04-01 2026-06-30 0001861657 CNTN:AppliedBiomedicalScienceInstituteMember 2026-01-01 2026-06-30 0001861657 CNTN:AppliedBiomedicalScienceInstituteMember 2025-04-01 2025-06-30 0001861657 CNTN:AppliedBiomedicalScienceInstituteMember 2025-01-01 2025-06-30 0001861657 CNTN:IntractPatentLicenseAgreementMember 2023-11-03 2023-11-03 0001861657 srt:MaximumMember 2023-11-03 2023-11-03 0001861657 CNTN:AviorPatentLicenseAgreementMember 2026-04-01 2026-06-30 0001861657 CNTN:AviorPatentLicenseAgreementMember 2026-01-01 2026-06-30 0001861657 CNTN:AviorPatentLicenseAgreementMember 2025-04-01 2025-06-30 0001861657 CNTN:AviorPatentLicenseAgreementMember 2025-01-01 2025-06-30 0001861657 CNTN:EnkefalosLicenseAgreementMember 2024-06-17 2024-06-17 0001861657 CNTN:EnkefalosLicenseAgreementMember 2026-04-01 2026-06-30 0001861657 CNTN:EnkefalosLicenseAgreementMember 2026-01-01 2026-06-30 0001861657 CNTN:EnkefalosLicenseAgreementMember 2025-04-01 2025-06-30 0001861657 CNTN:EnkefalosLicenseAgreementMember 2025-01-01 2025-06-30 0001861657 CNTN:IntractPatentLicenseAgreementMember 2024-09-11 2024-09-11 0001861657 CNTN:IntractPatentLicenseAgreementMember 2025-01-01 2025-06-30 0001861657 CNTN:IntractPatentLicenseAgreementMember 2026-04-01 2026-06-30 0001861657 CNTN:IntractPatentLicenseAgreementMember 2026-01-01 2026-06-30 0001861657 CNTN:IntractPatentLicenseAgreementMember 2025-04-01 2025-06-30 0001861657 CNTN:PresidentStreetGlobalMember us-gaap:RelatedPartyMember 2025-12-31 0001861657 us-gaap:SegmentDiscontinuedOperationsMember 2026-04-01 2026-06-30 0001861657 us-gaap:SegmentDiscontinuedOperationsMember 2026-01-01 2026-06-30 0001861657 CNTN:DigitalAssetTreasuryMember 2026-06-30 0001861657 CNTN:DigitalAssetTreasuryMember 2025-12-31 0001861657 CNTN:ClinicalStageBioTechnologyMember us-gaap:SegmentContinuingOperationsMember 2026-06-30 0001861657 CNTN:ClinicalStageBioTechnologyMember us-gaap:SegmentContinuingOperationsMember 2025-12-31 0001861657 CNTN:ClinicalStageBioTechnologyMember us-gaap:SegmentDiscontinuedOperationsMember 2026-06-30 0001861657 CNTN:ClinicalStageBioTechnologyMember us-gaap:SegmentDiscontinuedOperationsMember 2025-12-31 0001861657 CNTN:DigitalAssetTreasuryMember 2026-04-01 2026-06-30 0001861657 CNTN:DigitalAssetTreasuryMember 2025-04-01 2025-06-30 0001861657 CNTN:DigitalAssetTreasuryMember 2026-01-01 2026-06-30 0001861657 CNTN:DigitalAssetTreasuryMember 2025-01-01 2025-06-30 0001861657 CNTN:ClinicalStageBioTechnologyMember us-gaap:SegmentContinuingOperationsMember 2026-04-01 2026-06-30 0001861657 CNTN:ClinicalStageBioTechnologyMember us-gaap:SegmentContinuingOperationsMember 2025-04-01 2025-06-30 0001861657 CNTN:ClinicalStageBioTechnologyMember us-gaap:SegmentContinuingOperationsMember 2026-01-01 2026-06-30 0001861657 CNTN:ClinicalStageBioTechnologyMember us-gaap:SegmentContinuingOperationsMember 2025-01-01 2025-06-30 0001861657 CNTN:ClinicalStageBioTechnologyMember us-gaap:SegmentDiscontinuedOperationsMember 2026-04-01 2026-06-30 0001861657 CNTN:ClinicalStageBioTechnologyMember us-gaap:SegmentDiscontinuedOperationsMember 2025-04-01 2025-06-30 0001861657 CNTN:ClinicalStageBioTechnologyMember us-gaap:SegmentDiscontinuedOperationsMember 2026-01-01 2026-06-30 0001861657 CNTN:ClinicalStageBioTechnologyMember us-gaap:SegmentDiscontinuedOperationsMember 2025-01-01 2025-06-30 0001861657 CNTN:ClinicalStageBioTechnologyMember 2026-04-01 2026-06-30 0001861657 CNTN:ClinicalStageBioTechnologyMember 2025-04-01 2025-06-30 0001861657 CNTN:ClinicalStageBioTechnologyMember 2026-01-01 2026-06-30 0001861657 CNTN:ClinicalStageBioTechnologyMember 2025-01-01 2025-06-30 0001861657 CNTN:UnsecuredPromissoryNoteMember us-gaap:SubsequentEventMember CNTN:SecuritiesPurchaseAgreementMember 2026-07-17 iso4217:USD shares iso4217:USD shares pure CNTN:Integer CNTN:Segment false Q2 --12-31 0001861657 10-Q true 2026-06-30 2026 false 001-41210 CANTON STRATEGIC HOLDINGS, INC. DE 84-2642541 1460 Broadway New York NY 10036 (212) 210-6006 Not applicable Common stock, $0.0001 par value CNTN NASDAQ Yes Yes Non-accelerated Filer true true false false 79681361 37241568 12007148 3274069 197383 700997 5181535 41216634 17386066 523353752 501760369 564570386 519146435 916244 521201 983715 506460 726039 2258703 2625998 3286364 107041776 117934191 109667774 121220555 0.0001 0.0001 10000000 10000000 0 0 0 0 0.0001 0.0001 1000000000 1000000000 77273206 37112466 77272960 37112220 7727 3711 594380217 470809478 -139415367 -72817344 246 246 69965 69965 454902612 397925880 564570386 519146435 191226 191226 1304633 1304633 1495859 1495859 123638 215087 2698013 1304956 37919194 3257555 2698013 1428594 37919194 3472642 -1202154 -1428594 -36423335 -3472642 6161 14632 311848 2168 630026 15604 -23735950 -38749254 -23424102 -3993 -38119228 972 -24626256 -1432587 -74542563 -3471670 -6672175 -10892415 -17954081 -1432587 -63650148 -3471670 -1300745 -422566 -2947875 -925187 -19254826 -1855153 -66598023 -4396857 -0.08 -0.08 -0.50 -0.50 -0.30 -0.30 -1.27 -1.27 -0.01 -0.01 -0.15 -0.15 -0.01 -0.01 -0.34 -0.34 216864938 216864938 2877327 2877327 212310722 212310722 2725863 2725863 2108999 211 38697881 -39442798 246 -69965 -814671 240000 1551351 155 2259845 2260000 37332 163359 16 219531 219547 391157 39 -39 -10000 -10000 6300 1 8252 8253 -1855153 -1855153 559383 559383 4221166 422 41734853 -41297951 246 -69965 367359 1973999 198 38278503 -36901094 246 -69965 1307642 240000 1551351 155 2259845 2260000 37332 163359 16 219531 219547 491157 49 -49 200212 200212 35000 3 -3 -10000 -10000 6300 1 8252 8253 -4396857 -4396857 778562 778562 4221166 422 41734853 -41297951 246 -69965 367359 56656517 5665 590024159 -120160541 246 -69965 469799318 532895 1193159 119 4201276 4201395 17768864 1777 -1777 1609512 161 91707 91868 45154 5 -5 -5000 -5000 -19254826 -19254826 69857 69857 77273206 7727 594380217 -139415367 246 -69965 454902612 37112466 3711 470809478 -72817344 246 -69965 397925880 37112466 3711 470809478 -72817344 246 -69965 397925880 2195772 1800000 180 52698348 52698528 596875 9114338 911 39193898 39194809 9114338 911 39193898 39194809 27358876 2736 -2736 1674091 167 186412 186579 50834 6 -6 162601 16 -16 -834775 -834775 -66598023 -66598023 32329614 32329614 77273206 7727 594380217 -139415367 246 -69965 454902612 77273206 7727 594380217 -139415367 246 -69965 454902612 -66598023 -4396857 -2947875 -925187 -63650148 -3471670 1515630 -38749254 -10892415 32329614 430917 764031 150755 -158596 329453 477255 -225964 -5424697 -3088019 -4448795 -743512 -9873492 -3831531 59586023 1000000 -60586023 54894300 2500000 39791684 266625 186579 3627422 272246 285178 200638 64769 91245141 2514150 20785626 -1317381 17032748 3559361 37818374 2241980 576806 37241568 2241980 77083 24832 101102 314485 200212 <p id="xdx_80B_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zcv1LvQIgNM8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 1 – <span id="xdx_820_z1ZhOWc1nkde">Description of Business</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Nature of Operations</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canton Strategic Holdings, Inc., formerly known as Tharimmune, Inc. (“Canton Strategic,” “Tharimmune,” or the “Company”) was incorporated on March 28, 2017, as a Delaware C-corporation. The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, including Gravitas Life Sciences, Inc. (“Gravitas”), formerly known as Hillstream Oncology, Inc.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Digital Asset Treasury Strategy</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 6, 2025, in connection with a private placement with certain accredited investors (see Note 4 to the consolidated financial statements), Canton Strategic Holdings, Inc. announced the launch of a digital asset treasury strategy, pursuant to which the Company became the first publicly traded company to leverage Canton Coin (“CC”) and support the Canton Network to advance institutional blockchain adoption and the digitization of financial markets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the new treasury policy and strategy, the principal holding in our treasury reserve on the balance sheet will be allocated to digital assets, primarily CC by applying a public-market treasury model to an asset that is believed to be earlier in its lifecycle, structurally reflexive, and underexposed as compared to other digital assets. The planned approach involves acquiring CC directly through operation as a Super Validator and run additional Validators on the Canton Network as a mechanism to obtain additional CC.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 18, 2026, in conjunction with this strategy, the Company changed its name from Tharimmune, Inc. to Canton Strategic Holdings, Inc, pursuant to an amended and restated Certificate of Incorporation filed with the Delaware Secretary of State.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three months ended June 30, 2026, the Company adopted a plan to dispose of the clinical-stage biotechnology business which will allow management to focus resources on the Canton Network focused digital asset treasury strategy. See Note 11 for further information regarding disposal of the biotechnology business.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_80C_eus-gaap--SignificantAccountingPoliciesTextBlock_zjOQ6G05KBEf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 2 – <span id="xdx_827_zl77UlEmFINb">Summary of Significant Accounting Policies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zopW3u83DzEk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Basis of Presentation</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These interim unaudited condensed consolidated financial statements (the “Interim Statements”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and the rules and regulations of the Securities and Exchange Commission (the “SEC”) and do not include all of the information and footnotes required by U.S. GAAP for complete financial statements as certain information has been condensed or omitted. All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, these Interim Statements include all adjustments, which are of a normal recurring nature, necessary for a fair statement of the results for the interim periods presented. The results of operations for any interim period are not necessarily indicative of results for the full year. These Interim Statements should be read in conjunction with the audited consolidated financial statements and notes contained in the Company’s Annual Report on Form 10-K for the period ended December 31, 2025, as filed with the SEC (“2025 Annual Report”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--ConsolidationPolicyTextBlock_z2gLr7OqhOsf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Principles of Consolidation</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements include the accounts of Canton Strategic and its wholly-owned subsidiary, Gravitas. All significant intercompany balances and transactions have been eliminated in consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--DiscontinuedOperationsPolicyTextBlock_zSKO8JHWi0Wd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Discontinued Operations</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three months ended June 30, 2026, management committed to a plan for the divestiture of the Company’s wholly owned subsidiary, Gravitas. In accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 205-20, management evaluated the held for sale criteria under ASC 360-10-45-9 and concluded that Gravitas should be reported as discontinued operations in the financial statements included herein.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The assets and liabilities of the discontinued operations are aggregated and reported separately as assets and liabilities held for sale in the Condensed Consolidated Balance Sheets as of June 30, 2026 and December 31, 2025. The results of the discontinued operations are aggregated and presented separately in the Condensed Consolidated Statement of Operations as net loss from discontinued operations for the three and six months ended June 30, 2026 and 2025. The cash flows of the discontinued operations are reflected as cash flows from discontinued operations within the Condensed Consolidated Statement of Cash Flows for the six months ended June 30, 2026 and 2025.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amounts presented in assets and liabilities held for sale, and discontinued operations have been derived from our condensed consolidated financial statements and accounting records using the historical basis of assets, liabilities, results of operations, and cash flows of Gravitas business activities. See Note 10 for additional information on discontinued operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--RevenueRecognitionPolicyTextBlock_zAHqbhEqfSKc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Revenue Recognition</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company earns CC reward revenue through operating a Validator and Super Validator on the Canton Network. The Canton Network’s native token, CC, is issued under a burn-and-mint equilibrium model rather than a fixed block-reward schedule. New CC is minted approximately every ten minutes (a “round”) and allocated among three participant classes — Super Validators, Validators, and application providers — based on protocol-defined formulas. There is no identifiable counterparty that has contracted with the Company, negotiated terms, or agreed to pay consideration in exchange for a distinct good or service provided by the Company to that counterparty. As there is no customer or contract associated with the CC reward revenue, the Company applies the recognition and measurement principles of ASC 606 by analogy. The Company’s obligation is to provide validation/liveness services to the network for a given round. That obligation is satisfied — and the related reward is earned — at the completion of each round, when the Company has performed the requisite activity and the reward coupon becomes claimable/mintable. Rewards are received in CC, a non-cash asset. For purposes of applying ASC 606 by analogy, the Company considers its participation in each round to represent a separate arrangement and its validation and liveness activities for that round to represent a single performance obligation. No further performance obligations exist once a round’s reward is minted; there is no unsatisfied obligation requiring deferral of income into future periods. CC reward revenues are reported as Network validation revenue in the condensed consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company provides locking-as-a-service (“LAAS”) to Canton Network Super Validators and Featured Applications, which are required under Canton Improvement Proposals (“CIP”) 105 and 116 to maintain a qualifying amount of CC identifiably locked. The Company locks its own CC on the customer’s behalf in a segregated wallet at its qualified custodian, retaining legal and beneficial ownership throughout; only the wallet ID, not custody or title, is shared with the Canton Foundation. Because the CC is never transferred to the customer, it continues to be accounted for under the Company’s digital asset policy for the full arrangement term. Each arrangement is a contract with a single customer — the Super Validator or Featured Application — containing one performance obligation: a stand-ready obligation to keep the agreed CC balance locked and verifiable throughout the term. Consistent with ASC 606-10-25-27 through 25-29, this obligation is satisfied over time, as the customer simultaneously receives and consumes the benefit of continuous, verifiable locking. The Company is compensated under one of three structures: (i) a stated daily interest rate on the locked CC balance; (ii) a percentage of the customer’s Canton Network rewards, net of an expense offset in certain cases; or (iii) a grant of equity in the customer, earned ratably over a one-year term. LAAS revenue is reported within Other revenue in the condensed consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest / loan-type arrangements - Daily consideration is a fixed quantity of CC (rate × locked balance) that does not vary once accrued. This is noncash consideration under ASC 606-10-32-21 through 32-24; because the CC quantity itself is fixed, no variable-consideration constraint applies under ASC 606-10-32-11 through 32-13, as any resulting USD variability is attributable solely to the form of consideration (ASC 606-10-32-24). Revenue is recognized daily at fair value using that day’s end-of-day CC/USD reference rate, consistent with the right-to-invoice expedient (ASC 606-10-55-18), regardless of whether the counterparty ultimately settles in CC or USD.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue share arrangements - The Company’s percentage of monthly Canton Network rewards, net of any expense offset, is not fixed or determinable until month-end. Consistent with ASC 606-10-32-11 through 32-13, no interim estimate is recognized; revenue is recognized once, at month-end, in the finalized amount, translated at the month-end reference rate.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity compensation arrangement - Consideration is an equity grant measured at estimated fair value at contract inception under ASC 606-10-32-21 through 32-24, with subsequent changes in the equity’s value excluded from the transaction price per ASC 606-10-32-24. Revenue is recognized straight-line over the twelve-month service term, with a corresponding contract asset recognized until the equity is issued.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--DerivativesPolicyTextBlock_zmTnVAlhQVd5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Derivatives – Option Contracts</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the quarter ended June 30, 2026, the Company began entering into CC-denominated option contracts through the sale of collateral-secured put options, as a part of its digital asset strategy. These contracts meet the definition of derivative instruments under ASC 815, Derivatives and Hedging. The Company does not designate derivative instruments as hedging instruments for accounting purposes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for its CC-referenced option contracts as derivative instruments and recognizes them on the condensed consolidated balance sheets as assets or liabilities at fair value, with subsequent changes in fair value recognized in earnings. Premiums paid or received at contract inception are included in the initial fair value of the derivative instrument. If an option contract is exercised, the related derivative asset or liability is derecognized upon settlement. If an option contract expires unexercised, the related derivative asset or liability is derecognized upon expiration. Gains and losses related to CC option contracts, including fair value remeasurement and settlements, are recorded within Other revenue in the condensed consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CC options are not currently exchange traded, and the fair value of CC option contracts is determined using OTC dealer prices. The OTC dealer prices are classified within level 2 of the fair value hierarchy.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is required to post collateral with counterparties in connection with its CC option contracts, typically in the form of cash. Collateral posted is accounted for separately from the related derivative instrument and is not offset against derivative assets or liabilities. Collateral posted is presented within prepaid expenses and other current assets on the condensed consolidated balance sheets as the CC option contracts are less than 12 months duration. Cash flows associated with collateral on CC option contracts are reported as investing activities in the consolidated statements of cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of June 30, 2026 the fair value of the Company’s outstanding CC option contracts is a liability of $<span id="xdx_90A_eus-gaap--ContractWithCustomerLiability_iI_c20260630_zmgPH5q9n7Ze" title="Contracts liability">127,006</span>, recorded in Accrued expenses on the condensed consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--UseOfEstimates_zbb24Yd2N5F9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Use of Estimates</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Areas of the consolidated financial statements where estimates may have the most significant effect include fair value of cryptocurrency, research and development expense recognition, valuation of common shares and share-based compensation, allowances of deferred tax assets, valuation of debt related instruments, and cash flow assumptions regarding going concern considerations. Although management believes the estimates that have been used are reasonable, actual results could vary from the estimates that were used.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zNMaa1VBS4Cd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Segment Reporting</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has two reportable segments: digital assets and clinical stage bio-technology. The digital assets segment operates a CC-centric digital asset treasury strategy. The clinical stage bio-technology segment develops therapeutic candidates for rare, inflammatory and oncologic conditions. The clinical stage bio-technology segment is reported as held for sale discontinued operations. As the continuing operations represent only the digital assets segment, the Company will not include segment reporting in future periods. See Note 9 for additional information on the Company’s segments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--ConcentrationRiskCreditRisk_zR8EUZlnhF8e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Concentration of Credit Risk</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company maintains cash balances with various financial institutions. Account balances at these institutions are insured by the Federal Deposit Insurance Corporation up to $<span id="xdx_901_eus-gaap--CashFDICInsuredAmount_iI_c20260630_zau2XHIjXO01" title="FDIC insured amount">250,000</span> per depositor. At various times during the year, bank account balances may have been in excess of federally insured limits. The Company has not experienced losses in such accounts. The Company believes that it is not subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z6hv2fFm1Jgi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Cash and Cash Equivalents</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents, if any, are stated at cost and consist primarily of money market accounts.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_ecustom--DigitalAssetsPolicyTextBlock_zaPFah1mpsxj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Digital Assets</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for its digital assets, which are comprised of CC, as intangible assets in accordance with ASC 350-60, <i>Intangibles—Goodwill and Other-Crypto Assets</i>. The Company’s digital assets are initially recorded at cost and subsequently measured at fair value with the gain or loss associated with remeasurement of the digital assets recognized in net income (loss) during each reporting period. Upon disposal of a digital asset (e.g., by sale, exchange or transfer), the Company derecognizes the asset and recognizes a realized gain or loss in net income, calculated as the difference between the consideration received and the asset’s carrying amount.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of the Company’s digital assets is determined based on quoted prices in its principal market at the time of measurement. The Company determines its principal market as the market that it has access to and has the greatest volume and level of orderly transactions in accordance with FASB ASC 820, <i>Fair Value Measurement</i>. The Company tracks the cost of its digital assets using the first-in-first-out (FIFO) method.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_ecustom--DigitalAssetReceivablesPolicyTextBlock_zHGruaJK97Hg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Digital Asset Receivables</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s enters into contracts with customers for LAAS arrangements where settlement is denominated in CC. CC denominated receivables are remeasured at fair value during each reporting period with any associated gain or loss recognized in net income. The Company analogizes CC denominated receivables to a foreign currency denominated monetary asset under ASC 830. The Company determines fair value of CC receivables using the same pricing basis as digital assets under ASC 350-60.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--ResearchAndDevelopmentExpensePolicy_zXchwdhffMv8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Research and Development</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development costs are expensed as incurred. Research and development expenses include personnel costs associated with research and development activities, including third-party contractors to perform research, conduct clinical trials, and manufacture drug supplies and materials. These expenses also include costs associated with license fee arrangements and collaboration agreements, including milestone payments and ongoing license fees, which are also expensed as incurred. The Company accrues for costs incurred by external service providers, including contract research organizations and clinical investigators, based on its estimates of service performed and costs incurred. These estimates include the level of services performed by third parties, patient enrollment in clinical trials, administrative costs incurred by third parties, and other indicators of the services completed.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zzJ0PwRoR17e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Stock-Based Compensation</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes compensation costs resulting from the issuance of stock-based awards to employees, non-employees, and directors as an expense in the consolidated statements of operations over the requisite service period based on a measurement of fair value for each stock-based award. The fair value of common stock issued pursuant to termination agreements as well as restricted stock or restricted stock units is generally measured as the grant-date price of the Company’s common stock. The fair value of each option grant to employees, non-employees, and directors is estimated as of the date of grant using the Black-Scholes option-pricing model, net of actual forfeitures. The fair value is amortized as compensation cost on the straight-line basis over the requisite service period of the awards, which is generally the vesting period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior to January 12, 2022, the Company was a private company and the Company’s common stock has only been publicly traded since that date. As a result, the Company has limited company-specific historical and implied volatility information. Therefore, it has estimated its expected stock volatility based on the historical data of a publicly traded set of peer companies. The expected term of stock options granted was between five and seven years. The risk-free interest rate was determined by reference to the U.S. Treasury yield curve in effect at the time of grant for time periods approximately equal to the expected term of the award.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zDR9f4fShv6k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Fair Value Measurements</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company applies FASB ASC Topic 820, <i>Fair Value Measurement </i>(“ASC 820”), which establishes a framework for measuring fair value and clarifies the definition of fair value within that framework. ASC 820 defines fair value as an exit price, which is the price that would be received for an asset or paid to transfer a liability in the Company’s principal or most advantageous market in an orderly transaction between market participants on the measurement date. The fair value hierarchy established in ASC 820 generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entity’s own assumptions based on market data and the entity’s judgments about the assumptions that market participants would use in pricing the asset or liability and are to be developed based on the best information available in the circumstances.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The carrying value of the Company’s cash, prepaid expenses, accounts payable, and accrued expenses approximate fair value because of the short-term maturity of these financial instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The valuation hierarchy is composed of three levels. The classification within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The levels within the valuation hierarchy are described below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Level 1 Inputs: </i>Observable inputs such as quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Level 2 Inputs: </i>Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for assets or liabilities recently traded in active markets, with similar underlying terms, as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals, as well as quoted prices for identical or similar assets or liabilities in markets that are not active. </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Level 3 Inputs: </i>Unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities, that reflect the reporting entity’s own assumptions.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company applies ASC 820 in the valuation of CC held by the Company for financial statement purposes. The fair value of CC uses Level 1 inputs to reflect the price that would be received for CC in a current sale, which assumes an orderly transaction between market participants on the measurement date in CC’s “principal market,” or in the absence of a principal market, the most advantageous market. Market participants are defined as buyers and sellers in the principal or most advantageous market that are independent, knowledgeable, and willing and able to transact. The Company determines its principal market (or in the absence of a principal market, the most advantageous market) on a periodic basis to determine which market is its principal market for the purpose of calculating fair value for the creation of quarterly and annual financial statements. Issuer-specific events, market trends, bid/ask quotes of brokers and information providers and other data may be reviewed in the course of making a good faith determination of the digital asset’s fair value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--IncomeTaxPolicyTextBlock_zC1jVynR7Pek" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Income Taxes</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for income taxes using the asset-and-liability method in accordance with FASB ASC Topic 740, <i>Income Taxes</i> (“ASC 740”). Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred income taxes are recognized for the tax effect of temporary differences between the financial statement carrying amount of assets and liabilities and the amounts used for income tax purposes and for certain changes in valuation allowances. Valuation allowances are recorded to reduce certain deferred tax assets when, in management’s estimation, it is more-likely-than-not that a tax benefit will not be realized. A full valuation allowance has been recognized for all periods since it is more-likely-than-not that some portion or all of the deferred tax assets will not be realized in future periods.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company follows the guidance in FASB ASC Subtopic 740-10 in assessing uncertain tax positions. The standard applies to all tax positions and clarifies the recognition of tax benefits in the financial statements by providing for a two-step approach of recognition and measurement. The first step involves assessing whether the tax position is more-likely-than-not to be sustained upon examination based upon its technical merits. The second step involves measurement of the amount to be recognized. Tax positions that meet the more-likely-than-not threshold are measured at the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate finalization with the taxing authority. The Company recognizes the impact of an uncertain income tax position in the financial statements if it believes that the position is more-likely-than-not to be sustained by the relevant taxing authority. The Company will recognize interest and penalties related to tax positions in income tax expense. At June 30, 2026 and December 31, 2025, the Company had <span id="xdx_905_eus-gaap--UnrecognizedTaxBenefits_iI_do_c20260630_zBIczvU74Q2d" title="Unrecognized tax benefits"><span id="xdx_906_eus-gaap--UnrecognizedTaxBenefits_iI_do_c20251231_z4ktr97BbXck" title="Unrecognized tax benefits">no</span></span> unrecognized uncertain income tax positions, and therefore no amounts have been recognized in the consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_ecustom--PatentCostsPolicyTextBlock_zSOh6p9dyx2a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Patent Costs</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs associated with the submission of patent applications, including milestone fees and success fees, are expensed as incurred given the uncertainty of the future economic benefits of the patents. Patent and patent related legal and administrative costs are included in general and administrative expenses in the accompanying consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--EarningsPerSharePolicyTextBlock_zvi5qfZqPxjc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Net Loss per Share</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company reports loss per share in accordance with FASB ASC Subtopic 260-10, <i>Earnings Per Share</i>, which provides for calculation of basic and diluted earnings per share. Basic earnings per share includes no dilution and is computed by dividing net income or loss available to common stockholders by the weighted average common shares outstanding for the period. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of an entity. The calculation of diluted net earnings (loss) per share gives effect to common stock equivalents; however, potential common shares are excluded if their effect is anti-dilutive.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zdF2RpAPok4d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potentially dilutive securities not included in the computation of loss per share for the six months ended June 30, 2026 and 2025 are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BA_zix42Brw52Ze" style="display: none">Schedule of Potentially Dilutive Equity Shares not Included in Computation of EPS</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Statement - Condensed Consolidated Balance Sheets"> <tr style="display: none; vertical-align: bottom"> <td style="display: none"> </td><td style="display: none; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20260101__20260630_zkCxSggX0s9b" style="border-bottom: Black 1pt solid; display: none; text-align: center">2026</td><td style="display: none; padding-bottom: 1pt"> </td><td style="display: none; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20250101__20250630_zVlzB1C2uLO9" style="border-bottom: Black 1pt solid; display: none; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the six months ended June 30,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zrjmLfpUOrjl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Outstanding options to purchase shares of common stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">656,163</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">242,206</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zh1eMXZwzcU4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Warrants to purchase shares of common stock</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">11,630,321</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,639,797</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zeBr4sYYtrOc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total potentially dilutive securities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">12,286,484</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">3,882,003</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A9_zKfUtEcXJGN2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zAo58jiw2DP2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Recent Accounting Pronouncements</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2023, the FASB issued Accounting Standards Update (“ASU”) 2023-08<i>, Intangibles - Goodwill and Other - Crypto Assets (Subtopic 350-60): Accounting for and Disclosure of Crypto Assets</i>. This standard requires certain crypto assets meeting defined criteria to be measured at fair value each reporting period with changes in fair value recognized in net income, presented separately from other intangible assets and accompanied by enhanced disclosures. This standard was effective for fiscal years beginning after December 15,2024, with early adoption permitted. The Company adopted this standard during the year ended December 31, 2025 in conjunction with its new treasury strategy. Since the Company held no digital assets until November 2025, the adoption of this standard had no impact to prior reported financial statements and no cumulative adjustment to retained earnings was required or recorded.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2023, the FASB issued ASU 2023-07, <i>Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</i>, which requires expanded segment reporting and disclosure and is effective for the Company for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company adopted this guidance in the year ended December 31, 2025 as it previously did not have multiple reportable segments. This standard did not have a material impact on its financial statements other than enhanced disclosures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2023, the FASB issued ASU 2023-09, <i>Improvements to Income Tax Disclosures, </i>which expands income tax footnote disclosure requirements, including rate reconciliation and income taxes paid disclosures. The standard is effective for fiscal years beginning after December 15, 2024. The ASU affects disclosure only and does not impact the recognition or measurement of income taxes under ASC 740. Accordingly, adoption of ASU 2023-09 had no impact on the Company’s income tax provision.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2024, the FASB issued ASU 2024-03, <i>Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</i> and in January 2025, the FASB issued ASU No. 2025-01, <i>Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date</i>, which clarified the effective date of ASU 2024-03 for non-calendar year-end companies. ASU 2024-03 will require the Company to disclose the amounts of purchases of inventory, employee compensation, depreciation and intangible asset amortization, as applicable, included in certain expense captions in the consolidated statements of operations, as well as qualitatively describe remaining amounts included in those captions. ASU 2024-03 will also require the Company to disclose both the amount and the Company’s definition of selling expenses. This ASU is effective for fiscal years beginning after December 15, 2026 and interim periods within fiscal years beginning after December 31, 2027. The Company is currently evaluating the effects of the pronouncement on its consolidated financial statements.</span></p> <p id="xdx_85D_zeuAK2O1cgJ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zopW3u83DzEk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Basis of Presentation</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These interim unaudited condensed consolidated financial statements (the “Interim Statements”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and the rules and regulations of the Securities and Exchange Commission (the “SEC”) and do not include all of the information and footnotes required by U.S. GAAP for complete financial statements as certain information has been condensed or omitted. All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, these Interim Statements include all adjustments, which are of a normal recurring nature, necessary for a fair statement of the results for the interim periods presented. The results of operations for any interim period are not necessarily indicative of results for the full year. These Interim Statements should be read in conjunction with the audited consolidated financial statements and notes contained in the Company’s Annual Report on Form 10-K for the period ended December 31, 2025, as filed with the SEC (“2025 Annual Report”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--ConsolidationPolicyTextBlock_z2gLr7OqhOsf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Principles of Consolidation</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements include the accounts of Canton Strategic and its wholly-owned subsidiary, Gravitas. All significant intercompany balances and transactions have been eliminated in consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--DiscontinuedOperationsPolicyTextBlock_zSKO8JHWi0Wd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Discontinued Operations</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three months ended June 30, 2026, management committed to a plan for the divestiture of the Company’s wholly owned subsidiary, Gravitas. In accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 205-20, management evaluated the held for sale criteria under ASC 360-10-45-9 and concluded that Gravitas should be reported as discontinued operations in the financial statements included herein.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The assets and liabilities of the discontinued operations are aggregated and reported separately as assets and liabilities held for sale in the Condensed Consolidated Balance Sheets as of June 30, 2026 and December 31, 2025. The results of the discontinued operations are aggregated and presented separately in the Condensed Consolidated Statement of Operations as net loss from discontinued operations for the three and six months ended June 30, 2026 and 2025. The cash flows of the discontinued operations are reflected as cash flows from discontinued operations within the Condensed Consolidated Statement of Cash Flows for the six months ended June 30, 2026 and 2025.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amounts presented in assets and liabilities held for sale, and discontinued operations have been derived from our condensed consolidated financial statements and accounting records using the historical basis of assets, liabilities, results of operations, and cash flows of Gravitas business activities. See Note 10 for additional information on discontinued operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--RevenueRecognitionPolicyTextBlock_zAHqbhEqfSKc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Revenue Recognition</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company earns CC reward revenue through operating a Validator and Super Validator on the Canton Network. The Canton Network’s native token, CC, is issued under a burn-and-mint equilibrium model rather than a fixed block-reward schedule. New CC is minted approximately every ten minutes (a “round”) and allocated among three participant classes — Super Validators, Validators, and application providers — based on protocol-defined formulas. There is no identifiable counterparty that has contracted with the Company, negotiated terms, or agreed to pay consideration in exchange for a distinct good or service provided by the Company to that counterparty. As there is no customer or contract associated with the CC reward revenue, the Company applies the recognition and measurement principles of ASC 606 by analogy. The Company’s obligation is to provide validation/liveness services to the network for a given round. That obligation is satisfied — and the related reward is earned — at the completion of each round, when the Company has performed the requisite activity and the reward coupon becomes claimable/mintable. Rewards are received in CC, a non-cash asset. For purposes of applying ASC 606 by analogy, the Company considers its participation in each round to represent a separate arrangement and its validation and liveness activities for that round to represent a single performance obligation. No further performance obligations exist once a round’s reward is minted; there is no unsatisfied obligation requiring deferral of income into future periods. CC reward revenues are reported as Network validation revenue in the condensed consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company provides locking-as-a-service (“LAAS”) to Canton Network Super Validators and Featured Applications, which are required under Canton Improvement Proposals (“CIP”) 105 and 116 to maintain a qualifying amount of CC identifiably locked. The Company locks its own CC on the customer’s behalf in a segregated wallet at its qualified custodian, retaining legal and beneficial ownership throughout; only the wallet ID, not custody or title, is shared with the Canton Foundation. Because the CC is never transferred to the customer, it continues to be accounted for under the Company’s digital asset policy for the full arrangement term. Each arrangement is a contract with a single customer — the Super Validator or Featured Application — containing one performance obligation: a stand-ready obligation to keep the agreed CC balance locked and verifiable throughout the term. Consistent with ASC 606-10-25-27 through 25-29, this obligation is satisfied over time, as the customer simultaneously receives and consumes the benefit of continuous, verifiable locking. The Company is compensated under one of three structures: (i) a stated daily interest rate on the locked CC balance; (ii) a percentage of the customer’s Canton Network rewards, net of an expense offset in certain cases; or (iii) a grant of equity in the customer, earned ratably over a one-year term. LAAS revenue is reported within Other revenue in the condensed consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest / loan-type arrangements - Daily consideration is a fixed quantity of CC (rate × locked balance) that does not vary once accrued. This is noncash consideration under ASC 606-10-32-21 through 32-24; because the CC quantity itself is fixed, no variable-consideration constraint applies under ASC 606-10-32-11 through 32-13, as any resulting USD variability is attributable solely to the form of consideration (ASC 606-10-32-24). Revenue is recognized daily at fair value using that day’s end-of-day CC/USD reference rate, consistent with the right-to-invoice expedient (ASC 606-10-55-18), regardless of whether the counterparty ultimately settles in CC or USD.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue share arrangements - The Company’s percentage of monthly Canton Network rewards, net of any expense offset, is not fixed or determinable until month-end. Consistent with ASC 606-10-32-11 through 32-13, no interim estimate is recognized; revenue is recognized once, at month-end, in the finalized amount, translated at the month-end reference rate.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity compensation arrangement - Consideration is an equity grant measured at estimated fair value at contract inception under ASC 606-10-32-21 through 32-24, with subsequent changes in the equity’s value excluded from the transaction price per ASC 606-10-32-24. Revenue is recognized straight-line over the twelve-month service term, with a corresponding contract asset recognized until the equity is issued.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--DerivativesPolicyTextBlock_zmTnVAlhQVd5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Derivatives – Option Contracts</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the quarter ended June 30, 2026, the Company began entering into CC-denominated option contracts through the sale of collateral-secured put options, as a part of its digital asset strategy. These contracts meet the definition of derivative instruments under ASC 815, Derivatives and Hedging. The Company does not designate derivative instruments as hedging instruments for accounting purposes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for its CC-referenced option contracts as derivative instruments and recognizes them on the condensed consolidated balance sheets as assets or liabilities at fair value, with subsequent changes in fair value recognized in earnings. Premiums paid or received at contract inception are included in the initial fair value of the derivative instrument. If an option contract is exercised, the related derivative asset or liability is derecognized upon settlement. If an option contract expires unexercised, the related derivative asset or liability is derecognized upon expiration. Gains and losses related to CC option contracts, including fair value remeasurement and settlements, are recorded within Other revenue in the condensed consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CC options are not currently exchange traded, and the fair value of CC option contracts is determined using OTC dealer prices. The OTC dealer prices are classified within level 2 of the fair value hierarchy.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is required to post collateral with counterparties in connection with its CC option contracts, typically in the form of cash. Collateral posted is accounted for separately from the related derivative instrument and is not offset against derivative assets or liabilities. Collateral posted is presented within prepaid expenses and other current assets on the condensed consolidated balance sheets as the CC option contracts are less than 12 months duration. Cash flows associated with collateral on CC option contracts are reported as investing activities in the consolidated statements of cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of June 30, 2026 the fair value of the Company’s outstanding CC option contracts is a liability of $<span id="xdx_90A_eus-gaap--ContractWithCustomerLiability_iI_c20260630_zmgPH5q9n7Ze" title="Contracts liability">127,006</span>, recorded in Accrued expenses on the condensed consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 127006 <p id="xdx_842_eus-gaap--UseOfEstimates_zbb24Yd2N5F9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Use of Estimates</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Areas of the consolidated financial statements where estimates may have the most significant effect include fair value of cryptocurrency, research and development expense recognition, valuation of common shares and share-based compensation, allowances of deferred tax assets, valuation of debt related instruments, and cash flow assumptions regarding going concern considerations. Although management believes the estimates that have been used are reasonable, actual results could vary from the estimates that were used.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zNMaa1VBS4Cd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Segment Reporting</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has two reportable segments: digital assets and clinical stage bio-technology. The digital assets segment operates a CC-centric digital asset treasury strategy. The clinical stage bio-technology segment develops therapeutic candidates for rare, inflammatory and oncologic conditions. The clinical stage bio-technology segment is reported as held for sale discontinued operations. As the continuing operations represent only the digital assets segment, the Company will not include segment reporting in future periods. See Note 9 for additional information on the Company’s segments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--ConcentrationRiskCreditRisk_zR8EUZlnhF8e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Concentration of Credit Risk</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company maintains cash balances with various financial institutions. Account balances at these institutions are insured by the Federal Deposit Insurance Corporation up to $<span id="xdx_901_eus-gaap--CashFDICInsuredAmount_iI_c20260630_zau2XHIjXO01" title="FDIC insured amount">250,000</span> per depositor. At various times during the year, bank account balances may have been in excess of federally insured limits. The Company has not experienced losses in such accounts. The Company believes that it is not subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 250000 <p id="xdx_841_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z6hv2fFm1Jgi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Cash and Cash Equivalents</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents, if any, are stated at cost and consist primarily of money market accounts.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_ecustom--DigitalAssetsPolicyTextBlock_zaPFah1mpsxj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Digital Assets</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for its digital assets, which are comprised of CC, as intangible assets in accordance with ASC 350-60, <i>Intangibles—Goodwill and Other-Crypto Assets</i>. The Company’s digital assets are initially recorded at cost and subsequently measured at fair value with the gain or loss associated with remeasurement of the digital assets recognized in net income (loss) during each reporting period. Upon disposal of a digital asset (e.g., by sale, exchange or transfer), the Company derecognizes the asset and recognizes a realized gain or loss in net income, calculated as the difference between the consideration received and the asset’s carrying amount.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of the Company’s digital assets is determined based on quoted prices in its principal market at the time of measurement. The Company determines its principal market as the market that it has access to and has the greatest volume and level of orderly transactions in accordance with FASB ASC 820, <i>Fair Value Measurement</i>. The Company tracks the cost of its digital assets using the first-in-first-out (FIFO) method.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_ecustom--DigitalAssetReceivablesPolicyTextBlock_zHGruaJK97Hg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Digital Asset Receivables</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s enters into contracts with customers for LAAS arrangements where settlement is denominated in CC. CC denominated receivables are remeasured at fair value during each reporting period with any associated gain or loss recognized in net income. The Company analogizes CC denominated receivables to a foreign currency denominated monetary asset under ASC 830. The Company determines fair value of CC receivables using the same pricing basis as digital assets under ASC 350-60.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--ResearchAndDevelopmentExpensePolicy_zXchwdhffMv8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Research and Development</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development costs are expensed as incurred. Research and development expenses include personnel costs associated with research and development activities, including third-party contractors to perform research, conduct clinical trials, and manufacture drug supplies and materials. These expenses also include costs associated with license fee arrangements and collaboration agreements, including milestone payments and ongoing license fees, which are also expensed as incurred. The Company accrues for costs incurred by external service providers, including contract research organizations and clinical investigators, based on its estimates of service performed and costs incurred. These estimates include the level of services performed by third parties, patient enrollment in clinical trials, administrative costs incurred by third parties, and other indicators of the services completed.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zzJ0PwRoR17e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Stock-Based Compensation</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes compensation costs resulting from the issuance of stock-based awards to employees, non-employees, and directors as an expense in the consolidated statements of operations over the requisite service period based on a measurement of fair value for each stock-based award. The fair value of common stock issued pursuant to termination agreements as well as restricted stock or restricted stock units is generally measured as the grant-date price of the Company’s common stock. The fair value of each option grant to employees, non-employees, and directors is estimated as of the date of grant using the Black-Scholes option-pricing model, net of actual forfeitures. The fair value is amortized as compensation cost on the straight-line basis over the requisite service period of the awards, which is generally the vesting period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior to January 12, 2022, the Company was a private company and the Company’s common stock has only been publicly traded since that date. As a result, the Company has limited company-specific historical and implied volatility information. Therefore, it has estimated its expected stock volatility based on the historical data of a publicly traded set of peer companies. The expected term of stock options granted was between five and seven years. The risk-free interest rate was determined by reference to the U.S. Treasury yield curve in effect at the time of grant for time periods approximately equal to the expected term of the award.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zDR9f4fShv6k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Fair Value Measurements</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company applies FASB ASC Topic 820, <i>Fair Value Measurement </i>(“ASC 820”), which establishes a framework for measuring fair value and clarifies the definition of fair value within that framework. ASC 820 defines fair value as an exit price, which is the price that would be received for an asset or paid to transfer a liability in the Company’s principal or most advantageous market in an orderly transaction between market participants on the measurement date. The fair value hierarchy established in ASC 820 generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entity’s own assumptions based on market data and the entity’s judgments about the assumptions that market participants would use in pricing the asset or liability and are to be developed based on the best information available in the circumstances.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The carrying value of the Company’s cash, prepaid expenses, accounts payable, and accrued expenses approximate fair value because of the short-term maturity of these financial instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The valuation hierarchy is composed of three levels. The classification within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The levels within the valuation hierarchy are described below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Level 1 Inputs: </i>Observable inputs such as quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Level 2 Inputs: </i>Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for assets or liabilities recently traded in active markets, with similar underlying terms, as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals, as well as quoted prices for identical or similar assets or liabilities in markets that are not active. </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Level 3 Inputs: </i>Unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities, that reflect the reporting entity’s own assumptions.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company applies ASC 820 in the valuation of CC held by the Company for financial statement purposes. The fair value of CC uses Level 1 inputs to reflect the price that would be received for CC in a current sale, which assumes an orderly transaction between market participants on the measurement date in CC’s “principal market,” or in the absence of a principal market, the most advantageous market. Market participants are defined as buyers and sellers in the principal or most advantageous market that are independent, knowledgeable, and willing and able to transact. The Company determines its principal market (or in the absence of a principal market, the most advantageous market) on a periodic basis to determine which market is its principal market for the purpose of calculating fair value for the creation of quarterly and annual financial statements. Issuer-specific events, market trends, bid/ask quotes of brokers and information providers and other data may be reviewed in the course of making a good faith determination of the digital asset’s fair value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--IncomeTaxPolicyTextBlock_zC1jVynR7Pek" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Income Taxes</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for income taxes using the asset-and-liability method in accordance with FASB ASC Topic 740, <i>Income Taxes</i> (“ASC 740”). Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred income taxes are recognized for the tax effect of temporary differences between the financial statement carrying amount of assets and liabilities and the amounts used for income tax purposes and for certain changes in valuation allowances. Valuation allowances are recorded to reduce certain deferred tax assets when, in management’s estimation, it is more-likely-than-not that a tax benefit will not be realized. A full valuation allowance has been recognized for all periods since it is more-likely-than-not that some portion or all of the deferred tax assets will not be realized in future periods.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company follows the guidance in FASB ASC Subtopic 740-10 in assessing uncertain tax positions. The standard applies to all tax positions and clarifies the recognition of tax benefits in the financial statements by providing for a two-step approach of recognition and measurement. The first step involves assessing whether the tax position is more-likely-than-not to be sustained upon examination based upon its technical merits. The second step involves measurement of the amount to be recognized. Tax positions that meet the more-likely-than-not threshold are measured at the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate finalization with the taxing authority. The Company recognizes the impact of an uncertain income tax position in the financial statements if it believes that the position is more-likely-than-not to be sustained by the relevant taxing authority. The Company will recognize interest and penalties related to tax positions in income tax expense. At June 30, 2026 and December 31, 2025, the Company had <span id="xdx_905_eus-gaap--UnrecognizedTaxBenefits_iI_do_c20260630_zBIczvU74Q2d" title="Unrecognized tax benefits"><span id="xdx_906_eus-gaap--UnrecognizedTaxBenefits_iI_do_c20251231_z4ktr97BbXck" title="Unrecognized tax benefits">no</span></span> unrecognized uncertain income tax positions, and therefore no amounts have been recognized in the consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0 0 <p id="xdx_84A_ecustom--PatentCostsPolicyTextBlock_zSOh6p9dyx2a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Patent Costs</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs associated with the submission of patent applications, including milestone fees and success fees, are expensed as incurred given the uncertainty of the future economic benefits of the patents. Patent and patent related legal and administrative costs are included in general and administrative expenses in the accompanying consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--EarningsPerSharePolicyTextBlock_zvi5qfZqPxjc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Net Loss per Share</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company reports loss per share in accordance with FASB ASC Subtopic 260-10, <i>Earnings Per Share</i>, which provides for calculation of basic and diluted earnings per share. Basic earnings per share includes no dilution and is computed by dividing net income or loss available to common stockholders by the weighted average common shares outstanding for the period. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of an entity. The calculation of diluted net earnings (loss) per share gives effect to common stock equivalents; however, potential common shares are excluded if their effect is anti-dilutive.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zdF2RpAPok4d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potentially dilutive securities not included in the computation of loss per share for the six months ended June 30, 2026 and 2025 are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BA_zix42Brw52Ze" style="display: none">Schedule of Potentially Dilutive Equity Shares not Included in Computation of EPS</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Statement - Condensed Consolidated Balance Sheets"> <tr style="display: none; vertical-align: bottom"> <td style="display: none"> </td><td style="display: none; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20260101__20260630_zkCxSggX0s9b" style="border-bottom: Black 1pt solid; display: none; text-align: center">2026</td><td style="display: none; padding-bottom: 1pt"> </td><td style="display: none; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20250101__20250630_zVlzB1C2uLO9" style="border-bottom: Black 1pt solid; display: none; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the six months ended June 30,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zrjmLfpUOrjl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Outstanding options to purchase shares of common stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">656,163</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">242,206</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zh1eMXZwzcU4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Warrants to purchase shares of common stock</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">11,630,321</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,639,797</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zeBr4sYYtrOc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total potentially dilutive securities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">12,286,484</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">3,882,003</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A9_zKfUtEcXJGN2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zdF2RpAPok4d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potentially dilutive securities not included in the computation of loss per share for the six months ended June 30, 2026 and 2025 are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BA_zix42Brw52Ze" style="display: none">Schedule of Potentially Dilutive Equity Shares not Included in Computation of EPS</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Statement - Condensed Consolidated Balance Sheets"> <tr style="display: none; vertical-align: bottom"> <td style="display: none"> </td><td style="display: none; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20260101__20260630_zkCxSggX0s9b" style="border-bottom: Black 1pt solid; display: none; text-align: center">2026</td><td style="display: none; padding-bottom: 1pt"> </td><td style="display: none; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20250101__20250630_zVlzB1C2uLO9" style="border-bottom: Black 1pt solid; display: none; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the six months ended June 30,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zrjmLfpUOrjl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Outstanding options to purchase shares of common stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">656,163</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">242,206</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zh1eMXZwzcU4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Warrants to purchase shares of common stock</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">11,630,321</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,639,797</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zeBr4sYYtrOc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total potentially dilutive securities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">12,286,484</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">3,882,003</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 656163 242206 11630321 3639797 12286484 3882003 <p id="xdx_84F_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zAo58jiw2DP2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Recent Accounting Pronouncements</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2023, the FASB issued Accounting Standards Update (“ASU”) 2023-08<i>, Intangibles - Goodwill and Other - Crypto Assets (Subtopic 350-60): Accounting for and Disclosure of Crypto Assets</i>. This standard requires certain crypto assets meeting defined criteria to be measured at fair value each reporting period with changes in fair value recognized in net income, presented separately from other intangible assets and accompanied by enhanced disclosures. This standard was effective for fiscal years beginning after December 15,2024, with early adoption permitted. The Company adopted this standard during the year ended December 31, 2025 in conjunction with its new treasury strategy. Since the Company held no digital assets until November 2025, the adoption of this standard had no impact to prior reported financial statements and no cumulative adjustment to retained earnings was required or recorded.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2023, the FASB issued ASU 2023-07, <i>Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</i>, which requires expanded segment reporting and disclosure and is effective for the Company for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company adopted this guidance in the year ended December 31, 2025 as it previously did not have multiple reportable segments. This standard did not have a material impact on its financial statements other than enhanced disclosures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2023, the FASB issued ASU 2023-09, <i>Improvements to Income Tax Disclosures, </i>which expands income tax footnote disclosure requirements, including rate reconciliation and income taxes paid disclosures. The standard is effective for fiscal years beginning after December 15, 2024. The ASU affects disclosure only and does not impact the recognition or measurement of income taxes under ASC 740. Accordingly, adoption of ASU 2023-09 had no impact on the Company’s income tax provision.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2024, the FASB issued ASU 2024-03, <i>Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</i> and in January 2025, the FASB issued ASU No. 2025-01, <i>Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date</i>, which clarified the effective date of ASU 2024-03 for non-calendar year-end companies. ASU 2024-03 will require the Company to disclose the amounts of purchases of inventory, employee compensation, depreciation and intangible asset amortization, as applicable, included in certain expense captions in the consolidated statements of operations, as well as qualitatively describe remaining amounts included in those captions. ASU 2024-03 will also require the Company to disclose both the amount and the Company’s definition of selling expenses. This ASU is effective for fiscal years beginning after December 15, 2026 and interim periods within fiscal years beginning after December 31, 2027. The Company is currently evaluating the effects of the pronouncement on its consolidated financial statements.</span></p> <p id="xdx_804_eus-gaap--CryptoAssetTextBlock_zRnaBtcObTtb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 3 – <span id="xdx_82B_zs3USmmzPXf5">Digital Assets</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_892_eus-gaap--CryptoAssetHoldingTableTextBlock_zmZhX25A7z47" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table sets forth the units held, cost basis, and fair value of CC held, as shown on the consolidated balance sheet as of June 30, 2026 and December 31, 2025:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B2_zuNZtWvw5zT1" style="display: none">Schedule of Digital Assets Held</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Statement - Condensed Consolidated Balance Sheets"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20260630_zzf7fHmv1yqa" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20251231_zYG5AGjLmg9e" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Canton Coin</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--CryptoAssetNumberOfUnits_iI_uInteger_zLbXvo4yZDMi" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left">Units held</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">3,714,204,876</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">3,339,567,946</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--CryptoAssetCost_iI_zKdMDmsHbXQ3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Cost basis</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">584,064,579</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">523,770,731</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--CryptoAssetFairValue_iI_z8QsY2gcwTGl" style="vertical-align: bottom; background-color: White"> <td>Fair value</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">523,353,752</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">501,760,369</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A7_zXD7Cl1aArJj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost basis is equal to the cost of the digital asset, net of any transaction fees, if any, at the time of purchase or upon receipt. Fair value represents the quoted digital assets prices within the Company’s principal market at the time of measurement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_eus-gaap--CryptoAssetActivityTableTextBlock_za8Cn1mBTU22" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents a reconciliation of digital assets held as of June 30, 2026:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B8_z28KCS5Jaeyd" style="display: none">Schedule of Reconciliation of Digital Assets</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="display: none"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td id="xdx_490_20260101__20260630_z6OWfcJd39Va" style="display: none; text-align: right"> </td><td style="display: none; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--CryptoAssetFairValue_iS_zoAoFv8uJfe5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Fair value, December 31, 2025 balance</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">501,760,369</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--CryptoAssetPurchase_zpmhPZvFnBlc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Additions from CC purchases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">59,663,106</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--CryptoAssetCustomerReceipt_zSCXnhcfbl5j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Additions from CC receipts on network validation and other income</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">630,742</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--CryptoAssetRealizedAndUnrealizedGainLossOperatingAndNonoperating_zx6GOQjhFyQj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Unrealized losses</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(38,700,465</td><td style="text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--CryptoAssetFairValue_iE_zaOYnGkHJV8g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Fair value, June 30, 2026 balance</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">523,353,752</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AD_zmpsek0mz6J2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_892_eus-gaap--CryptoAssetHoldingTableTextBlock_zmZhX25A7z47" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table sets forth the units held, cost basis, and fair value of CC held, as shown on the consolidated balance sheet as of June 30, 2026 and December 31, 2025:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B2_zuNZtWvw5zT1" style="display: none">Schedule of Digital Assets Held</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Statement - Condensed Consolidated Balance Sheets"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20260630_zzf7fHmv1yqa" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20251231_zYG5AGjLmg9e" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Canton Coin</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--CryptoAssetNumberOfUnits_iI_uInteger_zLbXvo4yZDMi" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left">Units held</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">3,714,204,876</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">3,339,567,946</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--CryptoAssetCost_iI_zKdMDmsHbXQ3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Cost basis</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">584,064,579</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">523,770,731</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--CryptoAssetFairValue_iI_z8QsY2gcwTGl" style="vertical-align: bottom; background-color: White"> <td>Fair value</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">523,353,752</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">501,760,369</td><td style="text-align: left"> </td></tr> </table> 3714204876 3339567946 584064579 523770731 523353752 501760369 <p id="xdx_893_eus-gaap--CryptoAssetActivityTableTextBlock_za8Cn1mBTU22" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents a reconciliation of digital assets held as of June 30, 2026:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B8_z28KCS5Jaeyd" style="display: none">Schedule of Reconciliation of Digital Assets</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="display: none"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td id="xdx_490_20260101__20260630_z6OWfcJd39Va" style="display: none; text-align: right"> </td><td style="display: none; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--CryptoAssetFairValue_iS_zoAoFv8uJfe5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Fair value, December 31, 2025 balance</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">501,760,369</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--CryptoAssetPurchase_zpmhPZvFnBlc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Additions from CC purchases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">59,663,106</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--CryptoAssetCustomerReceipt_zSCXnhcfbl5j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Additions from CC receipts on network validation and other income</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">630,742</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--CryptoAssetRealizedAndUnrealizedGainLossOperatingAndNonoperating_zx6GOQjhFyQj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Unrealized losses</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(38,700,465</td><td style="text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--CryptoAssetFairValue_iE_zaOYnGkHJV8g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Fair value, June 30, 2026 balance</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">523,353,752</td><td style="text-align: left"> </td></tr> </table> 501760369 59663106 630742 -38700465 523353752 <p id="xdx_809_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zC3NSAZII2Zb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 4 – <span id="xdx_827_z8Rwe2Z7Wfsf">Common Stock</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the Company’s Certificate of Incorporation, as amended (filed October 10, 2025), the Company has <span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20260630_zAi8EvFsss69" title="Common stock, shares authorized">1,000,000,000</span> (previously <span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20250630_z0hqMRBVDjv3" title="Common stock, shares authorized">250,000,000</span>) shares of common stock authorized for issuance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 3, 2025, the Company entered into securities purchase agreements (the “Cash Securities Purchase Agreements”) with certain accredited investors (the “Cash Purchasers”) pursuant to which the Company agreed to sell and issue to the Cash Purchasers in a private placement offering (the “Cash Offering”) an aggregate of <span id="xdx_909_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20251103__20251103__us-gaap--TypeOfArrangementAxis__custom--CashSecuritiesPurchaseAgreementsMember_zYiMmQjcomUa" title="Aggregate sale amount of common stock">25,966,048</span> shares of common stock of the Company (the “Cash Shares”) and/or pre-funded warrants (the “Cash Pre-Funded Warrants”) to purchase <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251103__us-gaap--TypeOfArrangementAxis__custom--CashSecuritiesPurchaseAgreementsMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zgoTk87ZqtLj" title="Warrants to purchase shares">6,351,021</span> shares of common stock (the “Cash Pre-Funded Warrant Shares”) at an offering price of $<span id="xdx_90D_eus-gaap--SaleOfStockPricePerShare_iI_c20251103__us-gaap--TypeOfArrangementAxis__custom--CashSecuritiesPurchaseAgreementsMember_zVCYUq5I7dvi" title="Offering price, per share">3.075</span> per share (the “Per Share Cash Purchase Price”) for gross proceeds of approximately $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20251103__20251103__us-gaap--TypeOfArrangementAxis__custom--CashSecuritiesPurchaseAgreementsMember_z8WfEh8ypxtj" title="Proceeds from the common stock offering">99.4</span> million. Each of the Cash Pre-Funded Warrants is immediately exercisable for one share of common stock subject to certain beneficial ownership limitations set forth therein.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally, on November 3, 2025, the Company entered into securities purchase agreements (the “Cryptocurrency Securities Purchase Agreements”) with certain accredited investors (the “Cryptocurrency Purchasers”) pursuant to which the Company agreed to sell in a private placement (the “Cryptocurrency Offering”) pre-funded warrants (the “Cryptocurrency Pre-Funded Warrants”) to purchase <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251103__us-gaap--SubsidiarySaleOfStockAxis__custom--CryptocurrencyOfferingMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zZHjPKZmnWE8" title="Warrants to purchase shares">145,105,094</span> shares of common stock at an offering price of $<span id="xdx_900_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20251103__us-gaap--SubsidiarySaleOfStockAxis__custom--CryptocurrencyOfferingMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zGrgSFKB4RDi" title="Price per share">3.075</span> for gross proceeds in Canton Coin of approximately $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20251103__20251103__us-gaap--SubsidiarySaleOfStockAxis__custom--CryptocurrencyOfferingMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zQBMccX6TGVc" title="Gross proceeds from warrants">446.2</span> million. The Cryptocurrency Purchasers tendered Canton Coin to the Company as consideration for the Cryptocurrency Pre-Funded Warrants. Net proceeds to the Company from the combined Cash Offering and Cryptocurrency Offering were approximately $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20251103__20251103__us-gaap--SubsidiarySaleOfStockAxis__custom--CashOfferingAndCryptocurrencyOfferingMember_zX26Tvooovkb" title="Net proceeds from offering">537.1</span> million after deducting $<span id="xdx_90C_eus-gaap--PaymentsOfStockIssuanceCosts_pn5n6_c20251103__20261103__us-gaap--SubsidiarySaleOfStockAxis__custom--CashOfferingAndCryptocurrencyOfferingMember_zwItKp92Kpra" title="Stock issance costs">8.5</span> million in offering costs. Both the Cash Offering and Cryptocurrency Offering closed on November 6, 2025.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In conjunction with the Cash Securities Purchase Agreements and the Cryptocurrency Securities Purchase Agreements, the Company issued strategic advisor warrants to purchase up to <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20251103__us-gaap--TypeOfArrangementAxis__custom--CashSecuritiesPurchaseAgreementsAndCrytocurrencySecuritiesPurchaseAgreementsMember__us-gaap--StatementEquityComponentsAxis__custom--StrategicAdvisorWarrantsMember_z2jTlkiomIJg" title="Warrants to purchase common stock">10,318,215</span> shares of the Company’s common stock, exercisable at $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20251103__us-gaap--TypeOfArrangementAxis__custom--CashSecuritiesPurchaseAgreementsAndCrytocurrencySecuritiesPurchaseAgreementsMember__us-gaap--StatementEquityComponentsAxis__custom--StrategicAdvisorWarrantsMember_zFLDmkgGZtC4" title="Warrants exercise price per share">0.001</span> per share (the “Strategic Advisor Warrants”). In accordance with Nasdaq Listing Rule 5635(a), the issuance of shares pursuant to the Strategic Advisor Warrants were approved by shareholders on January 30, 2026.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 6, 2025, the Company entered into an at-the-market agreement (the “2025 ATM Agreement”) with Clear Street LLC and President Street Global LLC (the “ATM Sales Agents”) under which the Company may sell, from time to time through the ATM Sales Agents, shares of common stock in one or more offerings up to a total dollar amount of $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn6n6_c20251106__20251106__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyFiveATMAgreementMember__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsidiarySaleOfStockAxis__custom--AtMarketEquityOfferingsMember_zWabh2oq6fIg" title="Stock issued during period value at market equity offerings">65</span> million. On December 3, 2025 President Street Global LLC provided notice to the Company terminating participation in the 2025 ATM Agreement, leaving Clear Street LLC as the sole ATM Sales Agent. Sales of shares of the Company’s common stock through the ATM Sales Agent, if any, will be made by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415(a)(4) under the Securities, including, without limitation, sales made directly on the Nasdaq Stock Market LLC or any other existing trading market for the common shares. The Company’s common stock was being offered and sold pursuant to the Company’s effective shelf registration statement on Form S-3 and an accompanying prospectus declared effective by the SEC on March 24, 2023, and pursuant to a prospectus supplement dated November 7, 2025. As of December 31, 2025, the Company had sold <span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyFiveATMAgreementMember_zbLje0yZOWKf" title="Number of shares sold">1,657,799</span> shares of common stock pursuant to the 2025 ATM Agreement for net proceeds of approximately $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyFiveATMAgreementMember_zps6eThhRTi9" title="Net proceeds from sale of shares">5.1</span> million after deducting commissions of approximately $<span id="xdx_903_eus-gaap--DeferredOfferingCosts_iI_pn5n6_c20251231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyFiveATMAgreementMember_z1y4S7LsaLU" title="Offering cost">0.1</span> million.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 21, 2026, the Company closed an underwritten direct offering for <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20260121__20260121__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7OGHFbkaWph" title="Shares of common stock">1,800,000</span> shares of its common stock, par value $<span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20260121__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zeeArxdinJU3" title="Common stock, par value">0.0001</span> per share at an offering price of $<span id="xdx_905_eus-gaap--SaleOfStockPricePerShare_iI_c20260121__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zYX4rlhouS18" title="Price per share">2.92</span> per share and pre-funded warrants to purchase up to <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20260121__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_z7vHxWFvNE9b" title="Warrants to purchase common stock">17,000,000</span> shares of common stock at an offering price of $<span id="xdx_904_eus-gaap--SaleOfStockPricePerShare_iI_c20260121__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zl48Z7MOO74c" title="Offering price">2.9199</span> per pre-funded warrant. The exercise price of each pre-funded warrant is $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_c20260121_z8eDeSOo1bP2" title="Shares issued price">0.0001</span> per share (the “January 2026 Offering”). Net proceeds to the Company for the January 2026 Offering were approximately $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfWarrants_pn5n6_c20260121__20260121_zsIbzGKx6US1" title="Proceeds from pre-funded warrants">52.7</span> million after deducting $<span id="xdx_909_eus-gaap--PaymentsOfStockIssuanceCosts_pn5n6_c20260121__20260121_zyLnIWTPmEyl" title="Stock issance cost">2.2</span> million in offering costs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The January 2026 Offering was made pursuant to the Company’s shelf registration statement on Form S-3 (Registration Statement No. 333-292648), including the prospectus included therein, previously filed with the SEC and which became effective on January 16, 2026, and a prospectus supplement and the accompanying prospectus filed with the SEC pursuant to Rule 424(b) under the Securities Act.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 18, 2026, the Company’s common stock began trading under the ticker symbol, “CNTN.”</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 3, 2026, the Company entered into an amended and restated sales agreement (the “March 2026 ATM Agreement”), with Clear Street and Virtu Americas LLC (“Virtu”, and together with Clear Street, the “Sales Agents”), relating to the sale of shares of the Company’s common stock. The sales agreement amends and restates the 2025 ATM Agreement. Pursuant to the March 2026 ATM Agreement, the aggregate gross sales price of common stock available for issuance under the March 2026 Agreement is $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20260303__20260303__us-gaap--TypeOfArrangementAxis__custom--MarchTwoThousandTwentySixATMAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__custom--AtMarketEquityOfferingsMember_z7lanQ8tc6uj" title="Stock issued during period value st market equity offerings">300,000,000</span> and such amount excludes the common stock previously sold under the 2025 ATM Agreement. The Company’s common stock is being offered and sold pursuant to the Company’s effective shelf registration statement on Form S-3 (Registration Statement No. 333-292648), including the prospectus included therein, previously filed with the SEC which became effective on January 16, 2026. For the six months ended June 30, 2026 the Company has sold <span id="xdx_905_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20260101__20260630__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyFiveATMAgreementMember_zcJQZKjDFXL1" title="Number of shares sold">9,114,338</span> shares of common stock pursuant to the 2025 ATM Agreement and March 2026 ATM Agreement for net proceeds of approximately $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20260101__20260630__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyFiveATMAgreementMember_zRiF9j1tM90d" title="Proceeds from sale of stock">39.2</span> million after deducting commissions of approximately $<span id="xdx_903_eus-gaap--PaymentsOfStockIssuanceCosts_pn5n6_c20260101__20260630__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyFiveATMAgreementMember_zHGgzTMh2Lm4" title="Stock issance cost">0.6</span> million.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 1000000000 250000000 25966048 6351021 3.075 99400000 145105094 3.075 446200000 537100000 8500000 10318215 0.001 65000000 1657799 5100000 100000 1800000 0.0001 2.92 17000000 2.9199 0.0001 52700000 2200000 300000000 9114338 39200000 600000 <p id="xdx_809_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zFcpPB6WknYb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 5 – <span id="xdx_821_znva5dxhn122">Stock Based Compensation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Incentive Plans and Options</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the Company’s 2017 Stock Incentive Plan (the “2017 Plan”) the Company could grant incentive stock options, non-statutory stock options, rights to purchase common stock, stock appreciation rights, restricted stock, performance shares, and performance units to employees, directors, and consultants of the Company and its affiliates. Up to <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20260630__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenStockIncentivePlanMember_zsYU2AneMLL1" title="Shares authorized for issuance">261</span> shares of the Company’s common stock could be issued pursuant to the 2017 Plan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company granted options to acquire <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20260101__20260630__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenStockIncentivePlanMember_zgqDwjlfQYNe" title="Options granted in period">255</span> shares of common stock at $<span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_c20260630__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenStockIncentivePlanMember_zQIbmNf9Qcgl" title="Exercise price of option">4,950</span> per share under the 2017 Plan. During the six months ended June 30, 2026, options to acquire <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20260101__20260630__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenStockIncentivePlanMember_zKZlUhD38QMj" title="Number of shares available for forfeited">120</span> shares of common stock were forfeited. At June 30, 2026 there were no options outstanding. At December 31, 2025, there were <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251231__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenStockIncentivePlanMember_zHhNexE2dV35" title="Number of options, outstanding">120</span> options outstanding to acquire shares of common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In July 2019, the Company authorized the 2019 Stock Incentive Plan (the “2019 Plan”). Under the 2019 Plan, the Company could grant incentive stock options, non-statutory stock options, rights to purchase common stock, stock appreciation rights, restricted stock, performance shares, and performance units to employees, directors, and consultants of the Company and its affiliates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company granted options to acquire <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20260101__20260630__us-gaap--PlanNameAxis__custom--TwoThousandNineteenStockIncentivePlanMember_zqdRvHF55QGk" title="Options granted in period">10,452</span> shares of common stock under the 2019 Plan, of which <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20260101__20260630__us-gaap--PlanNameAxis__custom--TwoThousandNineteenStockIncentivePlanMember_zki1jep50qJ1" title="Stock option, exercised">4,940</span> were exercised. During the six months ended June 30, 2026, options to acquire <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20260101__20260630__us-gaap--PlanNameAxis__custom--TwoThousandNineteenStockIncentivePlanMember_zJIi8R8whv7b" title="Number of shares available for forfeited">759</span> shares of common stock were forfeited. There are stock options outstanding to acquire <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20260630__us-gaap--PlanNameAxis__custom--TwoThousandNineteenStockIncentivePlanMember_zmsDWWrZazF" title="Number of options, outstanding">134</span> shares of common stock with a weighted-average exercise price of $<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20260630__us-gaap--PlanNameAxis__custom--TwoThousandNineteenStockIncentivePlanMember_z95zFuVftgY" title="Weighted average exercise prices">498.75</span> and weighted average contractual terms of <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--PlanNameAxis__custom--TwoThousandNineteenStockIncentivePlanMember_zgF6P9YfbGX8" title="Weighted average contractual terms">5.7</span> years at June 30, 2026. At December 31, 2025 there were <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20251231__us-gaap--PlanNameAxis__custom--TwoThousandNineteenStockIncentivePlanMember_zvJJHgE1EpRa" title="Number of options, outstanding">893</span> options outstanding to acquire shares of common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 17, 2023, the Company authorized the Tharimmune, Inc. 2023 Omnibus Incentive Plan (as amended, the “2023 Plan”). Under the 2023 Plan, the Company may grant incentive stock options, non-statutory stock options, rights to purchase common stock, stock appreciation rights, restricted stock, performance shares, and performance units to employees, directors, and consultants of the Company and its affiliates. Under an amendment and restatement to the 2023 Plan approved by the Company’s stockholders on May 14, 2024, an “evergreen” provision was added to automatically increase the number of shares available under the 2023 Plan on January 1 annually, beginning January 1, 2025 and ending January 1, 2033, equal to the lesser of five percent of the shares of common stock outstanding (on an as-converted basis) on the final day of the immediately preceding calendar year or such lesser number of shares of the Company’s common stock as determined by the Board of Directors. Effective January 1, 2025, an additional <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20250101__20250101__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeOmnibusEquityIncentivePlanMember_zEXeCkmkFf3j" title="Number of shares authorized for issuance">98,688</span> shares of the Company’s common stock were added to the 2023 Plan, effective June 10, 2025, the shareholders approved an amendment to the 2023 Plan, increasing the 2023 Plan by <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20250610__20250610__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeOmnibusEquityIncentivePlanMember_zolxCyjK82Lb" title="Number of shares authorized for issuance">520,314</span> shares, effective October 9, 2025, the shareholders approved an additional amendment to the 2023 Plan, increasing the 2023 Plan by <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20251009__20251009__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeOmnibusEquityIncentivePlanMember_zDcE6xpN84y1" title="Number of shares authorized for issuance">1,207,398</span> shares, to a total of <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20251009__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeOmnibusEquityIncentivePlanMember_zQlT8NWdr8Vg" title="Number of shares authorized for issuance">2,000,000</span> shares available under the 2023 Plan. On January 30, 2026 shareholders approved an amendment to the 2023 Plan, increasing the shares authorized by <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20260129__20260129__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeOmnibusEquityIncentivePlanMember_zbgYywf9ccgd" title="Number of shares authorized for issuance">7,000,000</span> to a total of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20260130__20260130__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeOmnibusEquityIncentivePlanMember_ziGyKrCFZZR4" title="Number of shares authorized for issuance">9,000,000</span>. <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20260101__20260630__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeOmnibusEquityIncentivePlanMember_zK9OFsoXFiua" title="Number of shares authorized for issuance">7,793,342</span> and <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20250101__20251231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeOmnibusEquityIncentivePlanMember_zRNrPvgsTFQ8" title="Number of shares authorized for issuance">802,671</span> shares of common stock remained available for issuance under the 2023 Plan as of June 30, 2026 and December 31, 2025, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the six months ended June 30, 2026 and 2025, the Company granted <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20260101__20260630__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeOmnibusEquityIncentivePlanMember_zBQlDQ3zvYR5" title="Options granted in period">0</span> and <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20250101__20250630__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeOmnibusEquityIncentivePlanMember_z9KJnJnk7483" title="Options granted in period">133,833</span> options to acquire shares of common stock under the 2023 Plan, respectively. During the six months ended June 30, 2026 and 2025, there were <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_do_c20260101__20260630__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeOmnibusEquityIncentivePlanMember_zfRPmNWGaCJ9" title="Options forfeited in period"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_do_c20250101__20250630__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeOmnibusEquityIncentivePlanMember_zEd2tHjwMP75" title="Options forfeited in period">no</span></span> options forfeited or exercises under the 2023 Plan. As of June 30, 2026 there were stock options outstanding to acquire <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20260630__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeOmnibusEquityIncentivePlanMember_zwH5A8WPsBK8" title="Number of options, outstanding">656,029</span> shares of common stock with a weighted-average exercise price of $<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20260630__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeOmnibusEquityIncentivePlanMember_zqeFnbdUY4c3" title="Weighted average exercise prices">1.94</span> and weighted-average contractual terms of <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeOmnibusEquityIncentivePlanMember_zJk1Xo39iB5l" title="Weighted average contractual term">9.1</span> years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zFqfb9a12B2g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes stock-based activities under the 2017 Plan, 2019 Plan, and 2023 Stock Incentive Plans:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B6_z2CV8pEvsdbi" style="display: none">Schedule of Stock Option Activity</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Weighted</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Weighted</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">Shares</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Average</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Average</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">Underlying</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Exercise</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Contractual</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Options</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Price</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Terms</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Outstanding at December 31, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20260101__20260630_z3QDKKaOnE9d" style="width: 14%; text-align: right" title="Shares underlying option, outstanding, beginning balance">657,042</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20260101__20260630_zWWVT8fvdPV2" style="width: 14%; text-align: right" title="Weighted average exercise price, outstanding, beginning balance">4.32</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231_zHJuLqrF3AAc" title="Weighted average contractual terms outstanding">9.5</span> years</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Forfeited</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20260101__20260630_z1olz6fsxSH7" style="border-bottom: Black 1pt solid; text-align: right" title="Shares underlying option, Forfeited">(879</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20260101__20260630_zGv1TVfsqX4i" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Forfeited">1,626.87</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding at June 30, 2026</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20260101__20260630_zcmJY10C3Ir8" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares underlying option, outstanding, ending balance">656,163</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20260101__20260630_zTtSlfdOV4t9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, outstanding, ending balance">2.04</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630_zSDjygEoPd4" title="Weighted average contractual terms, outstanding">9.1</span> years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercisable options at June 30, 2026</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20260101__20260630_zqb6uGwZFza6" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares underlying option, exercisable">656,163</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20260101__20260630_z2lQ8nA0QwB2" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable">2.04</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260101__20260630_z9s04EsI6Vde" title="Weighted average contractual terms, exercisable">9.1</span> years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Vested and expected to vest at June 30, 2026</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_c20260101__20260630_zdIXcFDboru8" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares underlying option, vested and expected to vest">656,163</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20260101__20260630_zrFarRHtRd2h" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, vested and expected to vest">2.04</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20260101__20260630_zikxhRWTyRf3" title="Weighted average contractual terms, vested and expected to vest">9.1</span> years</span></td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A6_zDbHjpJEnpwi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of stock option awards is estimated at the date of grant using the Black-Scholes option-pricing model. The estimated fair value of each stock option is then expensed over the requisite service period, which is generally the vesting period (ranging between immediate vesting and four years). The determination of fair value using the Black-Scholes model is affected by the Company’s share price as well as assumptions regarding a number of complex and subjective variables, including expected price volatility, expected life, risk-free interest rate and forfeitures. Forfeitures are accounted for as they occur.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zrWsfTxOq1Z" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock options granted during the six months ended June 30, 2026 and 2025 were valued using the Black-Scholes option-pricing model with the following weighted-average assumptions:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B2_zdvJ0oHmJl7g" style="display: none">Schedule of Options Weighted Average Assumptions</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%" summary="xdx: Statement - Condensed Consolidated Balance Sheets"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the six months ended June 30,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Expected volatility</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zsATmwMfga5k" title="Expected volatility">102.3</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zkaf3WopcfRd" title="Risk-free interest rate">4.61</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zuJOUk1TD98j" title="Expected dividend yield">0</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Expected life of options in years</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z0VwiNaUXRg6" title="Expected life of options in years">5.0</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Estimated fair value of options granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20250630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zMpYwzgYvWDk" title="Estimated fair value of options granted">1.5</span></td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A0_zX4eLWcu45k6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There were no options granted in the six months ended June 30, 2026. The weighted-average grant date fair value of stock options granted during the six months ended June 30, 2025 was approximately $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20250101__20250630_zf86GVAfWNPi" title="Weighted average grant date fair value of stock options granted">1.50</span>. There were no options that vested in the six months ended June 30, 2026. All options granted were fully vested as of December 31, 2025. The weighted-average fair value of stock options vested during the three and six months ended June 30, 2025 was approximately $<span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20250401__20250630_zacKttTcsxNi" title="Weighted average fair value of stock options vested">13.36</span> and $<span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20250101__20250630_zmBaDQnGdEi" title="Weighted average fair value of stock options vested">17.70</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zvUemC2Nh8el" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total stock-based compensation expense included in the accompanying consolidated statements of operations was as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B9_zLk80xBc0D2l" style="display: none">Schedule of Stock-Based Compensation Expense</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="display: none"> </td><td style="display: none"> </td> <td colspan="2" id="xdx_499_20260401__20260630_z9m7QFTROXv3" style="border-bottom: Black 1pt solid; display: none; text-align: center">2026</td><td style="display: none"> </td><td style="display: none"> </td> <td colspan="2" id="xdx_493_20250401__20250630_zMQPWmIAVHS8" style="border-bottom: Black 1pt solid; display: none; text-align: center">2025</td><td style="display: none"> </td><td style="display: none"> </td> <td colspan="2" id="xdx_495_20260101__20260630_zfHqAIdVWh54" style="border-bottom: Black 1pt solid; display: none; text-align: center">2026</td><td style="display: none"> </td><td style="display: none"> </td> <td colspan="2" id="xdx_499_20250101__20250630_zUheLeBM4FI3" style="border-bottom: Black 1pt solid; display: none; text-align: center">2025</td><td style="display: none"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the three months ended June 30,</td><td> </td><td> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the six months ended June 30,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td> </td></tr> <tr id="xdx_404_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--StatementOfIncomeLocationBalanceAxis__us-gaap--IncomeLossFromDiscontinuedOperationsNetOfTax__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentDiscontinuedOperationsMember_zbZP2CWYdpwd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left">Discontinued Operations</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1040">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">262,033</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1042">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">355,898</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--StatementOfIncomeLocationBalanceAxis__us-gaap--GeneralAndAdministrativeExpense_zGiC9j45Z1Ph" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">General and administrative</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">69,857</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">305,603</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">32,329,614</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">430,917</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--StatementOfIncomeLocationBalanceAxis__us-gaap--ShareBasedCompensation_z0S67dPe9dFd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total stock-based compensation</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">69,857</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">567,636</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">32,329,614</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">786,815</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A9_zeZAtkTSE6r6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of June 30, 2026, there was <span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_do_c20260630_zwvFDTntCqD9" title="Unrecognized compensation expense">no</span> unrecognized compensation expense related to non-vested options.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Warrants</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has issued warrants to purchase shares of common stock in connection with various offerings, including those described in Note 4. The exercise of the Cryptocurrency Pre-Funded Warrants into common stock was subject to shareholder approval, and was approved on January 30, 2026 at a special meeting.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Strategic Advisor Warrants are compensatory and the issuance of shares pursuant to their exercise was approved by shareholders on January 30, 2026 so the Company recorded $<span id="xdx_904_eus-gaap--AllocatedShareBasedCompensationExpense_c20260101__20260630__us-gaap--StatementClassOfStockAxis__custom--StrategicAdvisorWarrantsMember_ze4WY4bG2H69" title="Stock based compensation expense">31,728,511</span> of stock-based compensation expense for the six months ended June 30, 2026. The Strategic Advisor Warrants were valued at $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--StatementClassOfStockAxis__custom--StrategicAdvisorWarrantsMember_zMTo69gQwvA2" title="Warrants per share">3.075</span>, the per share offering price of the Cash Offering and Cryptocurrency Offering which closed on November 6, 2025.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zDKltsXt7KXk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Terms of the warrants outstanding at June 30, 2026 are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B0_znhQuAlMphw5" style="display: none">Schedule of Warrants</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td style="text-align: center">Initial</td><td> </td> <td style="text-align: center">Expiration</td><td> </td> <td colspan="2" style="text-align: center">Exercise</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Warrants</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Warrants</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Warrants</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; text-align: center">Issuance Date</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: center">Exercise Date</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: center">Date</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Price</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Issued</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Exercised</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Outstanding</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 13%; text-align: center; padding-bottom: 2.5pt"><span id="xdx_90B_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsOneMember_zB7RNReR1h03" title="Warrants, Issuance Date">January 14, 2022</span></td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="width: 13%; text-align: center; padding-bottom: 2.5pt"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsOneMember_zVCBUNZBpwjc" title="Warrants, Initial Exercise Date">July 10, 2022</span></td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="width: 13%; text-align: center; padding-bottom: 2.5pt"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsOneMember_zEfZC5O3SjNb" title="Warrants, Expiration Date">January 11, 2027</span></td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsOneMember_zjmsqS3p2XW9" style="border-bottom: Black 2.5pt double; width: 11%; text-align: right" title="Warrants, Exercise Price">1,875.00</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"> </td><td id="xdx_984_ecustom--ClassOfWarrantOrRightIssued_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsOneMember_zLwAIVboVTcj" style="border-bottom: Black 2.5pt double; width: 10%; text-align: right" title="Warrants, Issued">500</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"> </td><td id="xdx_983_ecustom--ClassOfWarrantExercised_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsOneMember_zg4dP41gZ7ph" style="border-bottom: Black 2.5pt double; width: 10%; text-align: right" title="Warrant, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1073">-</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsOneMember_zcfr3C4VtTY6" style="border-bottom: Black 2.5pt double; width: 10%; text-align: right" title="Warrants, Outstanding">500</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_905_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwoMember_zh0rlBAwOI1b" title="Warrants, Issuance Date">May 2, 2023</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwoMember_zrbVXVZJVTB" title="Warrants, Initial Exercise Date">November 2, 2023</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwoMember_zgv7dXf5zI5j" title="Warrants, Expiration Date">May 2, 2028</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwoMember_zn6MEvbGlbih" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">234.375</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_ecustom--ClassOfWarrantOrRightIssued_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwoMember_zRCQio6lud55" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">424</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_ecustom--ClassOfWarrantExercised_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwoMember_zwTX8OqUFJqd" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrant, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1087">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwoMember_zkA9iqi1Esj" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">424</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_906_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsThreeMember_zPSFYZ9lLu6e" title="Warrants, Issuance Date">November 30, 2023</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsThreeMember_zsjJgVvPpX48" title="Warrants, Initial Exercise Date">May 27, 2024</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsThreeMember_zZiudK5wElx8" title="Warrants, Expiration Date">May 2, 2028</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsThreeMember_zYVKeBs2qwC8" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">18.75</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_ecustom--ClassOfWarrantOrRightIssued_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsThreeMember_zfemE0Jv64wj" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">20,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_ecustom--ClassOfWarrantExercised_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsThreeMember_z7AVTJNyddUb" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrant, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1101">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsThreeMember_zIIlCgpFDcol" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">20,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_903_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFourMember_zhHybqnuJJVd" title="Warrants, Issuance Date">June 21, 2024</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFourMember_zXEboN6UFIRg" title="Warrants, Initial Exercise Date">June 21, 2024</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt">N/A</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFourMember_zZptxtB8UZ3l" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">0.001</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_ecustom--ClassOfWarrantOrRightIssued_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFourMember_zOOyHsFXhmD6" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">452,253</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_ecustom--ClassOfWarrantExercised_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFourMember_zvp92wtcj4df" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">452,253</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFourMember_zHQGwlSoK8ah" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding"><span style="-sec-ix-hidden: xdx2ixbrl1115">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_905_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFiveMember_zp5uV3ACJb1l" title="Warrants, Issuance Date">June 21, 2024</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFiveMember_zS7RLcfjWfBj" title="Warrants, Initial Exercise Date">June 21, 2024</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFiveMember_zp0ffi4P672g" title="Warrants, Expiration Date">December 21, 2029</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFiveMember_zXD2goT4NDm4" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">3.09</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_ecustom--ClassOfWarrantOrRightIssued_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFiveMember_zknyPnlR1oC3" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">329,771</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_ecustom--ClassOfWarrantExercised_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFiveMember_z7NOAkBHhqg" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">229,430</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFiveMember_zqEnvMXicWuj" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">100,341</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_907_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSixMember_zbtWXDlzlmq" title="Warrants, Issuance Date">June 21, 2024</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSixMember_zPrSyfAmTwlk" title="Warrants, Initial Exercise Date">June 21, 2024</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSixMember_zaSpIzoVR14l" title="Warrants, Expiration Date">December 21, 2029</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSixMember_zjfUzl2DrfP5" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">3.06</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_ecustom--ClassOfWarrantOrRightIssued_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSixMember_zMHjBl8Y4IS3" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">39,573</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_ecustom--ClassOfWarrantExercised_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSixMember_zaGi3nh7WPtg" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1141">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSixMember_zZOeCem3JuBi" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">39,573</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_900_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSevenMember_zRVVCnSdcABd" title="Warrants, Issuance Date">December 9, 2024</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSevenMember_z8YddZQMCofb" title="Warrants, Initial Exercise Date">December 9, 2024</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt">N/A</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSevenMember_zKHcJASXqf06" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">0.001</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_ecustom--ClassOfWarrantOrRightIssued_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSevenMember_zW5T1oKhN3lk" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">491,157</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_ecustom--ClassOfWarrantExercised_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSevenMember_zwtOYwIff2xh" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">491,157</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSevenMember_zNm0hwcdlzO5" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding"><span style="-sec-ix-hidden: xdx2ixbrl1155">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_90B_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsEightMember_zptuJDB7se6e" title="Warrants, Issuance Date">December 9, 2024</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_90C_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsEightMember_zU6nKM4Uha34" title="Warrants, Initial Exercise Date">June 9, 2025</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsEightMember_zpaREZbhl5pa" title="Warrants, Expiration Date">December 9, 2030</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsEightMember_zmS0qRe2dku6" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">2.03</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_ecustom--ClassOfWarrantOrRightIssued_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsEightMember_zTjnZNPiVKw2" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">480,721</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_ecustom--ClassOfWarrantExercised_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsEightMember_zzUHADMrm2Ab" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">317,673</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsEightMember_zdYRlVtoM2Dc" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">163,048</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_90D_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsNineMember_zI3QDNimdgEf" title="Warrants, Issuance Date">December 9, 2024</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsNineMember_zme9vlMh74di" title="Warrants, Initial Exercise Date">June 9, 2025</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsNineMember_z1wFjMvzi5g2" title="Warrants, Expiration Date">December 9, 2030</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsNineMember_ze883T4tdTJd" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">2.031</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_ecustom--ClassOfWarrantOrRightIssued_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsNineMember_z2TXrF48X5q3" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">57,687</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_ecustom--ClassOfWarrantExercised_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsNineMember_zq8AcfrWQMA4" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1181">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsNineMember_zvzrV9ZBe3Yb" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">57,687</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_90A_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTenMember_zG2B4geLrbKa" title="Warrants, Issuance Date">June 20, 2025</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTenMember_zDs3kbLTgyKl" title="Warrants, Initial Exercise Date">June 20, 2025</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt">N/A</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTenMember_znpiOVbhiOxh" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">0.001</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_ecustom--ClassOfWarrantOrRightIssued_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTenMember_zvOkg3cdasW7" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">137,838</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_ecustom--ClassOfWarrantExercised_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTenMember_zXIEmKmVLqsb" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">137,838</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTenMember_zxRiiZDmmBde" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding"><span style="-sec-ix-hidden: xdx2ixbrl1195">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_90E_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsElevenMember_z4eW2XId5FBl" title="Warrants, Issuance Date">June 20, 2025</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_905_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsElevenMember_fKg_____zTN3RW2YvDJl" title="Warrants, Initial Exercise Date">December 20, 2025</span>*</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsElevenMember_fKg_____zLWSnJUBLvN2" title="Warrants, Expiration Date">June 20, 2031</span>*</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsElevenMember_zfa5uWc3XFUd" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">1.29</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_ecustom--ClassOfWarrantOrRightIssued_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsElevenMember_zfeXbpRBb4Rd" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">1,689,189</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_ecustom--ClassOfWarrantExercised_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsElevenMember_zVAdvdaiVGng" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">891,895</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsElevenMember_zBWEeyiCPaW4" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">797,294</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_908_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwelveMember_za6d1mDFFp3f" title="Warrants, Issuance Date">June 20, 2025</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_905_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwelveMember_fKg_____zW6fgxwoMBQ2" title="Warrants, Initial Exercise Date">December 20, 2025</span>*</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwelveMember_fKg_____z5z2jKm4eIf4" title="Warrants, Expiration Date">June 20, 2031</span>*</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwelveMember_z3qSe5UXrYv2" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">3.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_ecustom--ClassOfWarrantOrRightIssued_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwelveMember_zBKF7sqWIwTc" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">844,570</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_ecustom--ClassOfWarrantExercised_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwelveMember_zHa6VkY7kxti" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">114,862</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwelveMember_zKurcFj7uUue" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">729,708</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_90C_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsThirteenMember_zocTpLPgeY9" title="Warrants, Issuance Date">June 20, 2025</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsThirteenMember_znT9VMVc5gAj" title="Warrants, Initial Exercise Date">December 20, 2025</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsThirteenMember_zKt0BXmH70mf" title="Warrants, Expiration Date">June 20, 2031</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsThirteenMember_zywC43nsCxXj" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">1.29</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_ecustom--ClassOfWarrantOrRightIssued_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsThirteenMember_z1ODZckeuv1a" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">118,243</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_ecustom--ClassOfWarrantExercised_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsThirteenMember_zuj420otJCwh" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">6,739</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsThirteenMember_zG58Q3ASwyqa" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">111,504</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_90C_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFourteenMember_zH7TMFsYLkT4" title="Warrants, Issuance Date">June 20, 2025</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFourteenMember_zsNTx9o4ugh4" title="Warrants, Initial Exercise Date">December 20, 2025</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFourteenMember_zrcY5vLskm54" title="Warrants, Expiration Date">June 20, 2031</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFourteenMember_zx0kbToZkfI9" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">3.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_ecustom--ClassOfWarrantOrRightIssued_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFourteenMember_zqpvyP2eLU83" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">59,119</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_ecustom--ClassOfWarrantExercised_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFourteenMember_z1kFgZncWqpj" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1249">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFourteenMember_zJL54HMJvaLh" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">59,119</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_902_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFifteenMember_zrhRZ63uC8pf" title="Warrants, Issuance Date">July 25, 2025</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_90C_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFifteenMember_zYoHMrJknmp2" title="Warrants, Initial Exercise Date">July 25, 2025</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt">N/A</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFifteenMember_zwEDDGVuipc" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">0.001</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_ecustom--ClassOfWarrantOrRightIssued_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFifteenMember_zbmyQVUEfBpj" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">559,910</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_ecustom--ClassOfWarrantExercised_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFifteenMember_zLOUf86toGVj" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">559,910</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFifteenMember_zm3mwjfh16gb" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding"><span style="-sec-ix-hidden: xdx2ixbrl1263">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_900_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSixteenMember_z7lkeg4vJeMk" title="Warrants, Issuance Date">July 25, 2025</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSixteenMember_fKg_____zeicF44oEUdd" title="Warrants, Initial Exercise Date">January 25, 2026</span>*</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSixteenMember_fKg_____zlptwzp2Q65k" title="Warrants, Expiration Date">July 25, 2031</span>*</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSixteenMember_zSTXecBGtwe6" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">1.66</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_ecustom--ClassOfWarrantOrRightIssued_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSixteenMember_z8tiDvSuKe8h" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">974,241</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_ecustom--ClassOfWarrantExercised_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSixteenMember_zOkU5wVQe5ci" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">288,350</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSixteenMember_z7X1OGWCOWN7" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">685,891</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_901_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSeventeenMember_zfgIGrShJRgf" title="Warrants, Issuance Date">July 25, 2025</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSeventeenMember_zLOVCGEIiMP" title="Warrants, Initial Exercise Date">July 25, 2025</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt">N/A</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSeventeenMember_zrapHR8cmxpe" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">0.001</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_ecustom--ClassOfWarrantOrRightIssued_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSeventeenMember_zufDUS8khR0l" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">103,490</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_ecustom--ClassOfWarrantExercised_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSeventeenMember_zmfJQmjHfPSg" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">103,490</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSeventeenMember_zxQBGRNcMfxa" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding"><span style="-sec-ix-hidden: xdx2ixbrl1289">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_903_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsEighteenMember_zmJ8wazoj9Jk" title="Warrants, Issuance Date">July 25, 2025</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsEighteenMember_fKg_____zITyQUTgJih7" title="Warrants, Initial Exercise Date">January 25, 2026</span>*</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsEighteenMember_fKg_____zhoLjIbL605g" title="Warrants, Expiration Date">July 25, 2031</span>*</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsEighteenMember_ztLxNt5KkYPk" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">1.52</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_ecustom--ClassOfWarrantOrRightIssued_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsEighteenMember_zzGznlQbZsth" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">744,680</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_ecustom--ClassOfWarrantExercised_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsEighteenMember_zWVHKbQxUDWi" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">699,088</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsEighteenMember_zxnAxg3nLHC8" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">45,592</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_903_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsNineteenMember_zczNfZ4iDx2b" title="Warrants, Issuance Date">July 25, 2025</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsNineteenMember_zuSY04nT2wC7" title="Warrants, Initial Exercise Date">January 25, 2026</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsNineteenMember_zWeKkvxwg2e4" title="Warrants, Expiration Date">July 25, 2031</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsNineteenMember_zrIXabbC0IGc" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">1.66</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_ecustom--ClassOfWarrantOrRightIssued_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsNineteenMember_zEJWlOWt53Ia" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">52,128</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_ecustom--ClassOfWarrantExercised_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsNineteenMember_ztm7Nz7H54W8" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">2,971</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsNineteenMember_zJZi9mcnC7kj" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">49,157</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_909_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyMember_zbUICmhbZ1xl" title="Warrants, Issuance Date">August 26, 2025</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyMember_zsA51ITs75Og" title="Warrants, Initial Exercise Date">August 26, 2026</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt">N/A</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyMember_zQhfOX4j1PCg" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">0.001</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_ecustom--ClassOfWarrantOrRightIssued_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyMember_zLfTVOokgqpf" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">983,111</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_ecustom--ClassOfWarrantExercised_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyMember_zJmC8dzjORy3" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">983,111</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyMember_zrBD6C6swjEi" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding"><span style="-sec-ix-hidden: xdx2ixbrl1329">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_90C_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyOneMember_zuKM6Xqa1yQi" title="Warrants, Issuance Date">November 6, 2025</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyOneMember_zXGPjUEw4AEd" title="Warrants, Initial Exercise Date">November 6, 2025</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt">N/A</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyOneMember_zW7LMRl9MXIf" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">0.001</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_ecustom--ClassOfWarrantOrRightIssued_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyOneMember_zdtod16aDvOk" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">6,351,021</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_ecustom--ClassOfWarrantExercised_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyOneMember_zg6WGGC1Yraa" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1339">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyOneMember_zUYWS993tfXj" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">6,351,021</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_90C_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyTwoMember_zfNsk6uglWD1" title="Warrants, Issuance Date">November 6, 2025</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyTwoMember_zzXVLbpTWwwe" title="Warrants, Initial Exercise Date">November 6, 2025</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt">N/A</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyTwoMember_zJKES18nPMwe" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">0</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_ecustom--ClassOfWarrantOrRightIssued_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyTwoMember_zHhxawntrbhg" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">145,105,094</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_ecustom--ClassOfWarrantExercised_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyTwoMember_za4rRC7xWvpi" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">27,358,876</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyTwoMember_zgFm0HWIyph9" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">117,746,218</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_900_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyThreeMember_zCUo8UcTfJr3" title="Warrants, Issuance Date">November 6, 2025</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyThreeMember_zFTjkUBHAIj7" title="Warrants, Initial Exercise Date">January 30, 2026</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyThreeMember_znBgKlc86v94" title="Warrants, Expiration Date">January 30, 2031</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyThreeMember_zYjSHiAQf0ej" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">0.001</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_ecustom--ClassOfWarrantOrRightIssued_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyThreeMember_zbtVKpbB7TSa" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">10,318,215</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_ecustom--ClassOfWarrantExercised_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyThreeMember_zB3rb05JzSS3" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">1,547,732</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyThreeMember_z7oAQcvxHEJi" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">8,770,483</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_904_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyFourMember_zFplfp0aGQyd" title="Warrants, Issuance Date">January 21, 2026</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyFourMember_zXCoQ3cmwpAi" title="Warrants, Initial Exercise Date">January 21, 2026</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt">N/A</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyFourMember_zhSPFAy52fJ8" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">0.0001</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_ecustom--ClassOfWarrantOrRightIssued_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyFourMember_zvrUpAFxO9B" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">17,000,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_ecustom--ClassOfWarrantExercised_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyFourMember_z9pcXWGbQsgh" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1377">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyFourMember_zu03et1tQwn1" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">17,000,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F08_zkfCfKtuSku5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F17_zvwRzcZgUQCc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The exercise and expiration dates for the referenced common warrants were amended in October 2025 to reflect an exercise date of October 1, 2025.</span></td></tr> </table> <p id="xdx_8A3_zbeb15hi1Gn" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Restricted Stock Units</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the six months ended June 30, 2025, as stock-based consideration for consulting services, the Company granted restricted stock units (“RSUs”) under the 2023 Plan representing the right to receive <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zYtaJazpOu1b" title="Shares of common stock">35,000</span> shares of the Company’s common stock. During the six months ended June 30, 2026 as stock-based consideration for consulting services, the Company granted RSUs under the 2023 Plan representing the right to receive <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zfw7fbg0xlU5" title="Shares of common stock">15,000</span> shares of the Company’s common stock. <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_znJ77ghQizKi" title="Restricted stock units, description">The RSUs fully vested on June 30, 2026.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The grant date fair value of an RSU represents the closing price of the Company’s common stock on the date of grant. For those not vesting immediately, the estimated fair value of each RSU is then expensed over the requisite service period, which is generally the vesting period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The total stock compensation expense related to RSUs for the three and six months ended June 30, 2026 was $<span id="xdx_901_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20260401__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z6ldDTEMyDM5" title="Stock compensation expense">69,857</span> and $<span id="xdx_90C_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zggp58tN4TL6" title="Stock compensation expense">101,104</span>, respectively and for the three and six months ended June 30, 2025 was $<span id="xdx_908_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20250401__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z6qRdNolE8V1" title="Stock compensation expense">12,143</span> and $<span id="xdx_90A_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zwOrJ1e60Qh6" title="Stock compensation expense">20,417</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the six months ended June 30, 2026 the Company issued <span id="xdx_90A_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zGlpG9ThnCJg" title="Number of shares issued">162,601</span> shares of common stock to Clear Street LLC in connection with their services as an advisor in the Cash Offering and Cryptocurrency Offering which closed on November 6, 2025 (the “Advisor RSUs”). The Advisor RSUs share issuance was approved by shareholders during a special meeting on January 30, 2026. The Advisor RSUs were valued at $<span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_c20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zmID60unN8y9" title="Exercise price of option">3.075</span> per share, the per share offering price of the Cash Offering and Cryptocurrency Offering which closed on November 6, 2025. The company recorded $<span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zfaGcIBXSbr7" title="Stock compensation expense">499,998</span> of stock compensation expense related to the Advisor RSUs for the six months ended June 30, 2026.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 261 255 4950 120 120 10452 4940 759 134 498.75 P5Y8M12D 893 98688 520314 1207398 2000000 7000000 9000000 7793342 802671 0 133833 0 0 656029 1.94 P9Y1M6D <p id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zFqfb9a12B2g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes stock-based activities under the 2017 Plan, 2019 Plan, and 2023 Stock Incentive Plans:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B6_z2CV8pEvsdbi" style="display: none">Schedule of Stock Option Activity</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center">Weighted</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Weighted</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">Shares</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Average</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Average</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">Underlying</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Exercise</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Contractual</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Options</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Price</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Terms</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Outstanding at December 31, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20260101__20260630_z3QDKKaOnE9d" style="width: 14%; text-align: right" title="Shares underlying option, outstanding, beginning balance">657,042</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20260101__20260630_zWWVT8fvdPV2" style="width: 14%; text-align: right" title="Weighted average exercise price, outstanding, beginning balance">4.32</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231_zHJuLqrF3AAc" title="Weighted average contractual terms outstanding">9.5</span> years</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Forfeited</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20260101__20260630_z1olz6fsxSH7" style="border-bottom: Black 1pt solid; text-align: right" title="Shares underlying option, Forfeited">(879</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20260101__20260630_zGv1TVfsqX4i" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Forfeited">1,626.87</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding at June 30, 2026</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20260101__20260630_zcmJY10C3Ir8" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares underlying option, outstanding, ending balance">656,163</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20260101__20260630_zTtSlfdOV4t9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, outstanding, ending balance">2.04</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630_zSDjygEoPd4" title="Weighted average contractual terms, outstanding">9.1</span> years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercisable options at June 30, 2026</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20260101__20260630_zqb6uGwZFza6" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares underlying option, exercisable">656,163</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20260101__20260630_z2lQ8nA0QwB2" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable">2.04</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260101__20260630_z9s04EsI6Vde" title="Weighted average contractual terms, exercisable">9.1</span> years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Vested and expected to vest at June 30, 2026</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_c20260101__20260630_zdIXcFDboru8" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares underlying option, vested and expected to vest">656,163</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20260101__20260630_zrFarRHtRd2h" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, vested and expected to vest">2.04</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20260101__20260630_zikxhRWTyRf3" title="Weighted average contractual terms, vested and expected to vest">9.1</span> years</span></td><td style="text-align: left"> </td></tr> </table> 657042 4.32 P9Y6M 879 1626.87 656163 2.04 P9Y1M6D 656163 2.04 P9Y1M6D 656163 2.04 P9Y1M6D <p id="xdx_890_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zrWsfTxOq1Z" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock options granted during the six months ended June 30, 2026 and 2025 were valued using the Black-Scholes option-pricing model with the following weighted-average assumptions:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B2_zdvJ0oHmJl7g" style="display: none">Schedule of Options Weighted Average Assumptions</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%" summary="xdx: Statement - Condensed Consolidated Balance Sheets"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the six months ended June 30,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Expected volatility</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zsATmwMfga5k" title="Expected volatility">102.3</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zkaf3WopcfRd" title="Risk-free interest rate">4.61</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zuJOUk1TD98j" title="Expected dividend yield">0</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Expected life of options in years</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z0VwiNaUXRg6" title="Expected life of options in years">5.0</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Estimated fair value of options granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20250630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zMpYwzgYvWDk" title="Estimated fair value of options granted">1.5</span></td><td style="text-align: left"> </td></tr> </table> 1.023 0.0461 0 P5Y 1.5 1.50 13.36 17.70 <p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zvUemC2Nh8el" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total stock-based compensation expense included in the accompanying consolidated statements of operations was as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B9_zLk80xBc0D2l" style="display: none">Schedule of Stock-Based Compensation Expense</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="display: none"> </td><td style="display: none"> </td> <td colspan="2" id="xdx_499_20260401__20260630_z9m7QFTROXv3" style="border-bottom: Black 1pt solid; display: none; text-align: center">2026</td><td style="display: none"> </td><td style="display: none"> </td> <td colspan="2" id="xdx_493_20250401__20250630_zMQPWmIAVHS8" style="border-bottom: Black 1pt solid; display: none; text-align: center">2025</td><td style="display: none"> </td><td style="display: none"> </td> <td colspan="2" id="xdx_495_20260101__20260630_zfHqAIdVWh54" style="border-bottom: Black 1pt solid; display: none; text-align: center">2026</td><td style="display: none"> </td><td style="display: none"> </td> <td colspan="2" id="xdx_499_20250101__20250630_zUheLeBM4FI3" style="border-bottom: Black 1pt solid; display: none; text-align: center">2025</td><td style="display: none"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the three months ended June 30,</td><td> </td><td> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the six months ended June 30,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td> </td></tr> <tr id="xdx_404_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--StatementOfIncomeLocationBalanceAxis__us-gaap--IncomeLossFromDiscontinuedOperationsNetOfTax__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentDiscontinuedOperationsMember_zbZP2CWYdpwd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left">Discontinued Operations</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1040">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">262,033</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1042">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">355,898</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--StatementOfIncomeLocationBalanceAxis__us-gaap--GeneralAndAdministrativeExpense_zGiC9j45Z1Ph" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">General and administrative</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">69,857</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">305,603</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">32,329,614</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">430,917</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--StatementOfIncomeLocationBalanceAxis__us-gaap--ShareBasedCompensation_z0S67dPe9dFd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total stock-based compensation</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">69,857</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">567,636</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">32,329,614</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">786,815</td><td style="text-align: left"> </td></tr> </table> 262033 355898 69857 305603 32329614 430917 69857 567636 32329614 786815 0 31728511 3.075 <p id="xdx_89F_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zDKltsXt7KXk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Terms of the warrants outstanding at June 30, 2026 are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B0_znhQuAlMphw5" style="display: none">Schedule of Warrants</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td style="text-align: center">Initial</td><td> </td> <td style="text-align: center">Expiration</td><td> </td> <td colspan="2" style="text-align: center">Exercise</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Warrants</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Warrants</td><td> </td><td> </td> <td colspan="2" style="text-align: center">Warrants</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; text-align: center">Issuance Date</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: center">Exercise Date</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: center">Date</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Price</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Issued</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Exercised</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Outstanding</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 13%; text-align: center; padding-bottom: 2.5pt"><span id="xdx_90B_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsOneMember_zB7RNReR1h03" title="Warrants, Issuance Date">January 14, 2022</span></td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="width: 13%; text-align: center; padding-bottom: 2.5pt"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsOneMember_zVCBUNZBpwjc" title="Warrants, Initial Exercise Date">July 10, 2022</span></td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="width: 13%; text-align: center; padding-bottom: 2.5pt"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsOneMember_zEfZC5O3SjNb" title="Warrants, Expiration Date">January 11, 2027</span></td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsOneMember_zjmsqS3p2XW9" style="border-bottom: Black 2.5pt double; width: 11%; text-align: right" title="Warrants, Exercise Price">1,875.00</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"> </td><td id="xdx_984_ecustom--ClassOfWarrantOrRightIssued_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsOneMember_zLwAIVboVTcj" style="border-bottom: Black 2.5pt double; width: 10%; text-align: right" title="Warrants, Issued">500</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"> </td><td id="xdx_983_ecustom--ClassOfWarrantExercised_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsOneMember_zg4dP41gZ7ph" style="border-bottom: Black 2.5pt double; width: 10%; text-align: right" title="Warrant, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1073">-</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsOneMember_zcfr3C4VtTY6" style="border-bottom: Black 2.5pt double; width: 10%; text-align: right" title="Warrants, Outstanding">500</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_905_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwoMember_zh0rlBAwOI1b" title="Warrants, Issuance Date">May 2, 2023</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwoMember_zrbVXVZJVTB" title="Warrants, Initial Exercise Date">November 2, 2023</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwoMember_zgv7dXf5zI5j" title="Warrants, Expiration Date">May 2, 2028</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwoMember_zn6MEvbGlbih" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">234.375</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_ecustom--ClassOfWarrantOrRightIssued_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwoMember_zRCQio6lud55" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">424</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_ecustom--ClassOfWarrantExercised_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwoMember_zwTX8OqUFJqd" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrant, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1087">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwoMember_zkA9iqi1Esj" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">424</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_906_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsThreeMember_zPSFYZ9lLu6e" title="Warrants, Issuance Date">November 30, 2023</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsThreeMember_zsjJgVvPpX48" title="Warrants, Initial Exercise Date">May 27, 2024</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsThreeMember_zZiudK5wElx8" title="Warrants, Expiration Date">May 2, 2028</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsThreeMember_zYVKeBs2qwC8" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">18.75</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_ecustom--ClassOfWarrantOrRightIssued_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsThreeMember_zfemE0Jv64wj" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">20,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_ecustom--ClassOfWarrantExercised_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsThreeMember_z7AVTJNyddUb" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrant, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1101">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsThreeMember_zIIlCgpFDcol" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">20,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_903_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFourMember_zhHybqnuJJVd" title="Warrants, Issuance Date">June 21, 2024</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFourMember_zXEboN6UFIRg" title="Warrants, Initial Exercise Date">June 21, 2024</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt">N/A</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFourMember_zZptxtB8UZ3l" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">0.001</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_ecustom--ClassOfWarrantOrRightIssued_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFourMember_zOOyHsFXhmD6" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">452,253</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_ecustom--ClassOfWarrantExercised_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFourMember_zvp92wtcj4df" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">452,253</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFourMember_zHQGwlSoK8ah" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding"><span style="-sec-ix-hidden: xdx2ixbrl1115">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_905_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFiveMember_zp5uV3ACJb1l" title="Warrants, Issuance Date">June 21, 2024</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFiveMember_zS7RLcfjWfBj" title="Warrants, Initial Exercise Date">June 21, 2024</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFiveMember_zp0ffi4P672g" title="Warrants, Expiration Date">December 21, 2029</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFiveMember_zXD2goT4NDm4" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">3.09</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_ecustom--ClassOfWarrantOrRightIssued_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFiveMember_zknyPnlR1oC3" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">329,771</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_ecustom--ClassOfWarrantExercised_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFiveMember_z7NOAkBHhqg" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">229,430</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFiveMember_zqEnvMXicWuj" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">100,341</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_907_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSixMember_zbtWXDlzlmq" title="Warrants, Issuance Date">June 21, 2024</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSixMember_zPrSyfAmTwlk" title="Warrants, Initial Exercise Date">June 21, 2024</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSixMember_zaSpIzoVR14l" title="Warrants, Expiration Date">December 21, 2029</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSixMember_zjfUzl2DrfP5" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">3.06</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_ecustom--ClassOfWarrantOrRightIssued_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSixMember_zMHjBl8Y4IS3" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">39,573</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_ecustom--ClassOfWarrantExercised_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSixMember_zaGi3nh7WPtg" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1141">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSixMember_zZOeCem3JuBi" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">39,573</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_900_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSevenMember_zRVVCnSdcABd" title="Warrants, Issuance Date">December 9, 2024</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSevenMember_z8YddZQMCofb" title="Warrants, Initial Exercise Date">December 9, 2024</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt">N/A</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSevenMember_zKHcJASXqf06" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">0.001</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_ecustom--ClassOfWarrantOrRightIssued_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSevenMember_zW5T1oKhN3lk" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">491,157</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_ecustom--ClassOfWarrantExercised_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSevenMember_zwtOYwIff2xh" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">491,157</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSevenMember_zNm0hwcdlzO5" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding"><span style="-sec-ix-hidden: xdx2ixbrl1155">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_90B_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsEightMember_zptuJDB7se6e" title="Warrants, Issuance Date">December 9, 2024</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_90C_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsEightMember_zU6nKM4Uha34" title="Warrants, Initial Exercise Date">June 9, 2025</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsEightMember_zpaREZbhl5pa" title="Warrants, Expiration Date">December 9, 2030</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsEightMember_zmS0qRe2dku6" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">2.03</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_ecustom--ClassOfWarrantOrRightIssued_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsEightMember_zTjnZNPiVKw2" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">480,721</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_ecustom--ClassOfWarrantExercised_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsEightMember_zzUHADMrm2Ab" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">317,673</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsEightMember_zdYRlVtoM2Dc" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">163,048</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_90D_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsNineMember_zI3QDNimdgEf" title="Warrants, Issuance Date">December 9, 2024</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsNineMember_zme9vlMh74di" title="Warrants, Initial Exercise Date">June 9, 2025</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsNineMember_z1wFjMvzi5g2" title="Warrants, Expiration Date">December 9, 2030</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsNineMember_ze883T4tdTJd" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">2.031</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_ecustom--ClassOfWarrantOrRightIssued_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsNineMember_z2TXrF48X5q3" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">57,687</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_ecustom--ClassOfWarrantExercised_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsNineMember_zq8AcfrWQMA4" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1181">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsNineMember_zvzrV9ZBe3Yb" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">57,687</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_90A_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTenMember_zG2B4geLrbKa" title="Warrants, Issuance Date">June 20, 2025</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_90D_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTenMember_zDs3kbLTgyKl" title="Warrants, Initial Exercise Date">June 20, 2025</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt">N/A</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTenMember_znpiOVbhiOxh" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">0.001</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_ecustom--ClassOfWarrantOrRightIssued_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTenMember_zvOkg3cdasW7" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">137,838</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_ecustom--ClassOfWarrantExercised_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTenMember_zXIEmKmVLqsb" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">137,838</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTenMember_zxRiiZDmmBde" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding"><span style="-sec-ix-hidden: xdx2ixbrl1195">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_90E_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsElevenMember_z4eW2XId5FBl" title="Warrants, Issuance Date">June 20, 2025</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_905_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsElevenMember_fKg_____zTN3RW2YvDJl" title="Warrants, Initial Exercise Date">December 20, 2025</span>*</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsElevenMember_fKg_____zLWSnJUBLvN2" title="Warrants, Expiration Date">June 20, 2031</span>*</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsElevenMember_zfa5uWc3XFUd" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">1.29</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_ecustom--ClassOfWarrantOrRightIssued_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsElevenMember_zfeXbpRBb4Rd" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">1,689,189</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_ecustom--ClassOfWarrantExercised_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsElevenMember_zVAdvdaiVGng" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">891,895</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsElevenMember_zBWEeyiCPaW4" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">797,294</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_908_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwelveMember_za6d1mDFFp3f" title="Warrants, Issuance Date">June 20, 2025</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_905_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwelveMember_fKg_____zW6fgxwoMBQ2" title="Warrants, Initial Exercise Date">December 20, 2025</span>*</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwelveMember_fKg_____z5z2jKm4eIf4" title="Warrants, Expiration Date">June 20, 2031</span>*</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwelveMember_z3qSe5UXrYv2" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">3.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_ecustom--ClassOfWarrantOrRightIssued_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwelveMember_zBKF7sqWIwTc" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">844,570</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_ecustom--ClassOfWarrantExercised_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwelveMember_zHa6VkY7kxti" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">114,862</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwelveMember_zKurcFj7uUue" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">729,708</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_90C_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsThirteenMember_zocTpLPgeY9" title="Warrants, Issuance Date">June 20, 2025</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsThirteenMember_znT9VMVc5gAj" title="Warrants, Initial Exercise Date">December 20, 2025</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsThirteenMember_zKt0BXmH70mf" title="Warrants, Expiration Date">June 20, 2031</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsThirteenMember_zywC43nsCxXj" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">1.29</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_ecustom--ClassOfWarrantOrRightIssued_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsThirteenMember_z1ODZckeuv1a" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">118,243</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_ecustom--ClassOfWarrantExercised_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsThirteenMember_zuj420otJCwh" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">6,739</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsThirteenMember_zG58Q3ASwyqa" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">111,504</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_90C_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFourteenMember_zH7TMFsYLkT4" title="Warrants, Issuance Date">June 20, 2025</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFourteenMember_zsNTx9o4ugh4" title="Warrants, Initial Exercise Date">December 20, 2025</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFourteenMember_zrcY5vLskm54" title="Warrants, Expiration Date">June 20, 2031</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFourteenMember_zx0kbToZkfI9" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">3.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_ecustom--ClassOfWarrantOrRightIssued_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFourteenMember_zqpvyP2eLU83" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">59,119</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_ecustom--ClassOfWarrantExercised_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFourteenMember_z1kFgZncWqpj" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1249">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFourteenMember_zJL54HMJvaLh" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">59,119</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_902_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFifteenMember_zrhRZ63uC8pf" title="Warrants, Issuance Date">July 25, 2025</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_90C_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFifteenMember_zYoHMrJknmp2" title="Warrants, Initial Exercise Date">July 25, 2025</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt">N/A</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFifteenMember_zwEDDGVuipc" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">0.001</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_ecustom--ClassOfWarrantOrRightIssued_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFifteenMember_zbmyQVUEfBpj" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">559,910</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_ecustom--ClassOfWarrantExercised_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFifteenMember_zLOUf86toGVj" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">559,910</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsFifteenMember_zm3mwjfh16gb" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding"><span style="-sec-ix-hidden: xdx2ixbrl1263">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_900_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSixteenMember_z7lkeg4vJeMk" title="Warrants, Issuance Date">July 25, 2025</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSixteenMember_fKg_____zeicF44oEUdd" title="Warrants, Initial Exercise Date">January 25, 2026</span>*</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSixteenMember_fKg_____zlptwzp2Q65k" title="Warrants, Expiration Date">July 25, 2031</span>*</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSixteenMember_zSTXecBGtwe6" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">1.66</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_ecustom--ClassOfWarrantOrRightIssued_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSixteenMember_z8tiDvSuKe8h" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">974,241</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_ecustom--ClassOfWarrantExercised_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSixteenMember_zOkU5wVQe5ci" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">288,350</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSixteenMember_z7X1OGWCOWN7" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">685,891</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_901_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSeventeenMember_zfgIGrShJRgf" title="Warrants, Issuance Date">July 25, 2025</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSeventeenMember_zLOVCGEIiMP" title="Warrants, Initial Exercise Date">July 25, 2025</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt">N/A</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSeventeenMember_zrapHR8cmxpe" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">0.001</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_ecustom--ClassOfWarrantOrRightIssued_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSeventeenMember_zufDUS8khR0l" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">103,490</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_ecustom--ClassOfWarrantExercised_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSeventeenMember_zmfJQmjHfPSg" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">103,490</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsSeventeenMember_zxQBGRNcMfxa" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding"><span style="-sec-ix-hidden: xdx2ixbrl1289">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_903_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsEighteenMember_zmJ8wazoj9Jk" title="Warrants, Issuance Date">July 25, 2025</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsEighteenMember_fKg_____zITyQUTgJih7" title="Warrants, Initial Exercise Date">January 25, 2026</span>*</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsEighteenMember_fKg_____zhoLjIbL605g" title="Warrants, Expiration Date">July 25, 2031</span>*</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsEighteenMember_ztLxNt5KkYPk" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">1.52</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_ecustom--ClassOfWarrantOrRightIssued_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsEighteenMember_zzGznlQbZsth" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">744,680</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_ecustom--ClassOfWarrantExercised_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsEighteenMember_zWVHKbQxUDWi" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">699,088</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsEighteenMember_zxnAxg3nLHC8" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">45,592</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_903_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsNineteenMember_zczNfZ4iDx2b" title="Warrants, Issuance Date">July 25, 2025</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsNineteenMember_zuSY04nT2wC7" title="Warrants, Initial Exercise Date">January 25, 2026</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsNineteenMember_zWeKkvxwg2e4" title="Warrants, Expiration Date">July 25, 2031</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsNineteenMember_zrIXabbC0IGc" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">1.66</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_ecustom--ClassOfWarrantOrRightIssued_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsNineteenMember_zEJWlOWt53Ia" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">52,128</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_ecustom--ClassOfWarrantExercised_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsNineteenMember_ztm7Nz7H54W8" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">2,971</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsNineteenMember_zJZi9mcnC7kj" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">49,157</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_909_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyMember_zbUICmhbZ1xl" title="Warrants, Issuance Date">August 26, 2025</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyMember_zsA51ITs75Og" title="Warrants, Initial Exercise Date">August 26, 2026</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt">N/A</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyMember_zQhfOX4j1PCg" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">0.001</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_ecustom--ClassOfWarrantOrRightIssued_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyMember_zLfTVOokgqpf" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">983,111</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_ecustom--ClassOfWarrantExercised_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyMember_zJmC8dzjORy3" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">983,111</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyMember_zrBD6C6swjEi" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding"><span style="-sec-ix-hidden: xdx2ixbrl1329">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_90C_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyOneMember_zuKM6Xqa1yQi" title="Warrants, Issuance Date">November 6, 2025</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyOneMember_zXGPjUEw4AEd" title="Warrants, Initial Exercise Date">November 6, 2025</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt">N/A</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyOneMember_zW7LMRl9MXIf" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">0.001</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_ecustom--ClassOfWarrantOrRightIssued_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyOneMember_zdtod16aDvOk" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">6,351,021</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_ecustom--ClassOfWarrantExercised_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyOneMember_zg6WGGC1Yraa" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1339">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyOneMember_zUYWS993tfXj" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">6,351,021</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_90C_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyTwoMember_zfNsk6uglWD1" title="Warrants, Issuance Date">November 6, 2025</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyTwoMember_zzXVLbpTWwwe" title="Warrants, Initial Exercise Date">November 6, 2025</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt">N/A</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyTwoMember_zJKES18nPMwe" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">0</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_ecustom--ClassOfWarrantOrRightIssued_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyTwoMember_zHhxawntrbhg" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">145,105,094</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_ecustom--ClassOfWarrantExercised_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyTwoMember_za4rRC7xWvpi" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">27,358,876</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyTwoMember_zgFm0HWIyph9" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">117,746,218</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_900_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyThreeMember_zCUo8UcTfJr3" title="Warrants, Issuance Date">November 6, 2025</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyThreeMember_zFTjkUBHAIj7" title="Warrants, Initial Exercise Date">January 30, 2026</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyThreeMember_znBgKlc86v94" title="Warrants, Expiration Date">January 30, 2031</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyThreeMember_zYjSHiAQf0ej" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">0.001</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_ecustom--ClassOfWarrantOrRightIssued_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyThreeMember_zbtVKpbB7TSa" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">10,318,215</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_ecustom--ClassOfWarrantExercised_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyThreeMember_zB3rb05JzSS3" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised">1,547,732</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyThreeMember_z7oAQcvxHEJi" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">8,770,483</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_904_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsIssuance_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyFourMember_zFplfp0aGQyd" title="Warrants, Issuance Date">January 21, 2026</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_dd_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyFourMember_zXCoQ3cmwpAi" title="Warrants, Initial Exercise Date">January 21, 2026</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt">N/A</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyFourMember_zhSPFAy52fJ8" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercise Price">0.0001</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_ecustom--ClassOfWarrantOrRightIssued_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyFourMember_zvrUpAFxO9B" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Issued">17,000,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_ecustom--ClassOfWarrantExercised_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyFourMember_z9pcXWGbQsgh" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1377">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20260630__us-gaap--StatementEquityComponentsAxis__custom--WarrantsTwentyFourMember_zu03et1tQwn1" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants, Outstanding">17,000,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F08_zkfCfKtuSku5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F17_zvwRzcZgUQCc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The exercise and expiration dates for the referenced common warrants were amended in October 2025 to reflect an exercise date of October 1, 2025.</span></td></tr> </table> 2022-01-14 2022-07-10 2027-01-11 1875.00 500 500 2023-05-02 2023-11-02 2028-05-02 234.375 424 424 2023-11-30 2024-05-27 2028-05-02 18.75 20000 20000 2024-06-21 2024-06-21 0.001 452253 452253 2024-06-21 2024-06-21 2029-12-21 3.09 329771 229430 100341 2024-06-21 2024-06-21 2029-12-21 3.06 39573 39573 2024-12-09 2024-12-09 0.001 491157 491157 2024-12-09 2025-06-09 2030-12-09 2.03 480721 317673 163048 2024-12-09 2025-06-09 2030-12-09 2.031 57687 57687 2025-06-20 2025-06-20 0.001 137838 137838 2025-06-20 2025-12-20 2031-06-20 1.29 1689189 891895 797294 2025-06-20 2025-12-20 2031-06-20 3.00 844570 114862 729708 2025-06-20 2025-12-20 2031-06-20 1.29 118243 6739 111504 2025-06-20 2025-12-20 2031-06-20 3.00 59119 59119 2025-07-25 2025-07-25 0.001 559910 559910 2025-07-25 2026-01-25 2031-07-25 1.66 974241 288350 685891 2025-07-25 2025-07-25 0.001 103490 103490 2025-07-25 2026-01-25 2031-07-25 1.52 744680 699088 45592 2025-07-25 2026-01-25 2031-07-25 1.66 52128 2971 49157 2025-08-26 2026-08-26 0.001 983111 983111 2025-11-06 2025-11-06 0.001 6351021 6351021 2025-11-06 2025-11-06 0 145105094 27358876 117746218 2025-11-06 2026-01-30 2031-01-30 0.001 10318215 1547732 8770483 2026-01-21 2026-01-21 0.0001 17000000 17000000 35000 15000 The RSUs fully vested on June 30, 2026. 69857 101104 12143 20417 162601 3.075 499998 <p id="xdx_802_eus-gaap--IncomeTaxDisclosureTextBlock_z0B3VEju8bqg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 6 – <span id="xdx_82B_zvzEsz6LRJCb">Income Taxes</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zfCJon8w5Aeb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents the income tax provision (benefit) and effective tax rate:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B2_zxM29H65kMw2" style="display: none">Schedule of Effective Income Tax Rate and Income Tax Provision (benefit)</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Three Months Ended June 30,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Income tax provision (benefit)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--IncomeTaxExpenseBenefit_c20260401__20260630_zoaWMkm9rWEd" style="width: 16%; text-align: right" title="Effective income tax expense">(6,672,175</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--IncomeTaxExpenseBenefit_c20250401__20250630_zhQNBMY0NsW2" style="width: 16%; text-align: right" title="Income tax provision (benefit)"><span style="-sec-ix-hidden: xdx2ixbrl1408">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Effective tax rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_c20260401__20260630_zyXT86WZ1I8b" style="text-align: right" title="Effective income tax expense, percentage">27.0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_c20250401__20250630_zAFvV9jwBBr9" style="text-align: right" title="Effective income tax"><span style="-sec-ix-hidden: xdx2ixbrl1412">-</span></td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Income tax provision (benefit)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--IncomeTaxExpenseBenefit_c20260101__20260630_z387DOqThtJj" style="width: 16%; text-align: right" title="Effective income tax expense">(10,892,415</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--IncomeTaxExpenseBenefit_c20250101__20250630_zp7mzCIvWisi" style="width: 16%; text-align: right" title="Income tax provision (benefit)"><span style="-sec-ix-hidden: xdx2ixbrl1416">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Effective tax rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_c20260101__20260630_zigfh48Oi1jd" style="text-align: right" title="Effective income tax expense, percentage">14.6</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_c20250101__20250630_zPOWzuxEbdMd" style="text-align: right" title="Effective income tax"><span style="-sec-ix-hidden: xdx2ixbrl1420">-</span></td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A6_zW9TORnkbhV1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The effective tax rate reflects a full valuation allowance against net deferred tax assets, including tax loss carryforwards. The Company has recognized a deferred tax provision (benefit) in connection with unrealized gains or losses on Digital Assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zfCJon8w5Aeb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents the income tax provision (benefit) and effective tax rate:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B2_zxM29H65kMw2" style="display: none">Schedule of Effective Income Tax Rate and Income Tax Provision (benefit)</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Three Months Ended June 30,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Income tax provision (benefit)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--IncomeTaxExpenseBenefit_c20260401__20260630_zoaWMkm9rWEd" style="width: 16%; text-align: right" title="Effective income tax expense">(6,672,175</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--IncomeTaxExpenseBenefit_c20250401__20250630_zhQNBMY0NsW2" style="width: 16%; text-align: right" title="Income tax provision (benefit)"><span style="-sec-ix-hidden: xdx2ixbrl1408">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Effective tax rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_c20260401__20260630_zyXT86WZ1I8b" style="text-align: right" title="Effective income tax expense, percentage">27.0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_c20250401__20250630_zAFvV9jwBBr9" style="text-align: right" title="Effective income tax"><span style="-sec-ix-hidden: xdx2ixbrl1412">-</span></td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Income tax provision (benefit)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--IncomeTaxExpenseBenefit_c20260101__20260630_z387DOqThtJj" style="width: 16%; text-align: right" title="Effective income tax expense">(10,892,415</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--IncomeTaxExpenseBenefit_c20250101__20250630_zp7mzCIvWisi" style="width: 16%; text-align: right" title="Income tax provision (benefit)"><span style="-sec-ix-hidden: xdx2ixbrl1416">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Effective tax rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_c20260101__20260630_zigfh48Oi1jd" style="text-align: right" title="Effective income tax expense, percentage">14.6</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_c20250101__20250630_zPOWzuxEbdMd" style="text-align: right" title="Effective income tax"><span style="-sec-ix-hidden: xdx2ixbrl1420">-</span></td><td style="text-align: left"> </td></tr> </table> -6672175 0.270 -10892415 0.146 <p id="xdx_80D_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z4ghtAxYjWg4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 7 – <span id="xdx_823_zwCuNhplruIc">Commitments and Contingencies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Research Collaboration and Product License Agreement with Minotaur Therapeutics, Inc. (“Minotaur”) and Commercial License Agreement with Taurus Biosciences, LLC (“Taurus”)</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has entered into a research collaboration and product license agreement with Minotaur (as amended, the “Minotaur Agreement”) and a commercial license agreement with Taurus (the “Taurus Agreement”) for use of certain technology, including OmniAb antibodies, to advance Picobodies against novel, unreachable, and undruggable epitopes in high-value validated targets starting with PD-1. The Minotaur Agreement and Taurus Agreement are for the development of proprietary targeted biologics, including GV1940, against PD-1. Pursuant to the Minotaur Agreement the Company can collaborate with Minotaur under the license from Taurus to discover, develop, and advance biotherapeutics against high-value validated IO targets starting with PD-1.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Minotaur Agreement included an up-front payment of $<span id="xdx_90E_ecustom--UpfrontPayment_c20230101__20230131_zYIptw0da72" title="Upfront payment">150,000</span>, which was paid in January 2023. In addition, the Company shall fund the discovery and characterization study performed by Minotaur as set forth in the Minotaur Agreement. Pursuant to the Minotaur Agreement, the Company is required to pay Minotaur a milestone payment of $<span id="xdx_907_ecustom--FurtureMilestonePayment_c20230101__20230131_zx1KO2lSpnc4" title="Future payment upon meeting milestone">1,000,000</span> for each first Product (as defined in the Minotaur Agreement) directed against a target and first regulatory approval in the U.S. In addition, the Company is required to pay a low single digit royalty on net sales until the later of (i) ten years after the First Commercial Sale (as defined in the Minotaur Agreement) of such Product in such country and (ii) the expiration of the last-to-expire Valid Claim (as defined in the Minotaur Agreement) of a Collaboration Patent (as defined in the Minotaur Agreement) or MINT Patent (as defined in the Minotaur Agreement) covering the manufacture, use, or sale of such Product. The Taurus Agreement contains single digit payments on net product sales and certain development milestone payments tied to the advancement through clinical trials and final regulatory approval.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three and six months ended June 30, 2026 and 2025, the Company incurred <span id="xdx_905_ecustom--LicenseFees_do_c20260401__20260630__us-gaap--TypeOfArrangementAxis__custom--MinotaurAgreementMember_zUu8NeYb4uQc" title="License fees"><span id="xdx_908_ecustom--LicenseFees_do_c20260101__20260630__us-gaap--TypeOfArrangementAxis__custom--MinotaurAgreementMember_zngZUmPKjM2a" title="License fees"><span id="xdx_906_ecustom--LicenseFees_do_c20250401__20250630__us-gaap--TypeOfArrangementAxis__custom--MinotaurAgreementMember_zkbQ0HZo62ij" title="License fees"><span id="xdx_90B_ecustom--LicenseFees_do_c20250101__20250630__us-gaap--TypeOfArrangementAxis__custom--MinotaurAgreementMember_zMHGwbjJlPhl" title="License fees">no</span></span></span></span> fees to Minotaur. The Minotaur Agreement is included in continuing operations and is retained by the Company after the Gravitas Transaction (see Note 11).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Research and Development Collaboration and License Agreement with Applied Biomedical Science Institute</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 5, 2023 (the “ABSI Effective Date”), the Company entered into a Research and Development Collaboration and License Agreement (the “ABSI Agreement”) with ABSI pursuant to which ABSI granted the Company an exclusive royalty-bearing, sublicensable license to the ABSI Patents (as defined in the ABSI Agreement) and a non-exclusive, royalty-bearing, sublicensable license to the ABSI Know-How (as defined in the ABSI Agreement) to Exploit (as defined in the ABSI Agreement) the ABSI Products (as defined in the ABSI Agreement) for the treatment, diagnosis, prediction, detection or prevention of disease in humans and animals worldwide (the “Territory”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the ABSI Agreement, the parties are required to form a committee to manage the preclinical, investigational new drug enabling studies and such other activities as shall lead to the initiation of a Phase 1 clinical trial of the ABSI Product. The parties can collaborate on a Target-by-Target basis to identify and evaluate ABSI Products directed against such Target (as defined below) with a view to identifying or generating suitable Products (as defined in the ABSI Agreement) for the Company to Exploit. “Target” means ErB2 (Her2) and ErbB3. Upon completion of the Discovery Timeline (as defined in the ABSI Agreement) for a Target, subject to the terms and conditions of ABSI Agreement, the Company may exclusively own any ABSI Products against such Target. In the event the committee determines that the discovery activities are unsuccessful with respect to a Target, the Company may propose an additional target, which, upon approval by ABSI, would replace a failed Target.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the ABSI Agreement: (i) the Company issued ABSI <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230727__20230727__us-gaap--TypeOfArrangementAxis__custom--AppliedBiomedicalScienceInstituteMember_zlm0b43ZMTR5" title="Common stock issued">25,107</span> shares of its common stock which is equal to $<span id="xdx_90B_eus-gaap--StockIssued1_c20230727__20230727__us-gaap--TypeOfArrangementAxis__custom--AppliedBiomedicalScienceInstituteMember_z4o1hPGLHQU1" title="Value of common stock issued">250,000</span> based on the ten day trailing volume weighted-average price of the Company’s common stock prior to the date of issuance, (ii) in the event the Company closes a financing pursuant to which it receives more than $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn6n6_c20230704__20230705__us-gaap--TypeOfArrangementAxis__custom--ABSIMember_zTULOK5HVaf7" title="Net proceeds from offering">10</span> million in Net Proceeds (as defined in the ABSI Agreement), the Company would pay ABSI a mid-six digit amount; (iii) upon the achievement of certain milestones as set forth in the ABSI Agreement, the Company would pay ABSI up to an aggregate of $<span id="xdx_908_ecustom--MilestonePayment_c20230704__20230705__us-gaap--TypeOfArrangementAxis__custom--AppliedBiomedicalScienceInstituteMember__srt--RangeAxis__srt--MaximumMember_zYDheS7FuDJ7" title="ABSI shares issued, shares">8,250,000</span>; (iv) after the second anniversary of the ABSI Effective Date, the Company would pay ABSI a low five digit amount for the first year and a mid-five digit amount thereafter during the Royalty Term (as defined in the ABSI Agreement); and (v) during the Royalty Term for each Product, the Company shall pay ABSI a quarterly royalty on the Net Sales (as defined in the ABSI Agreement) with royalties at percentages which range from the low to mid-single digits, with high Net Sales being subject to lower royalty rates, subject to adjustment as set forth in the ABSI Agreement. In addition, in the event the Company transfers all or substantially all of its rights to a Product to a third party, the Company would pay to ABSI the percentage of Net Proceeds attributable to the transfer of the Product. Specifically, the Company would pay ABSI amounts at percentages which range from the mid-single digit to low double digits depending on the Company Expenses (as defined in the ABSI Agreement), with higher Company Expenses being subject to lower rates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On a Product-by-Product basis, upon the expiration of the last Royalty Term of such Product in the Territory, licenses granted to the Company with respect to such Product would be deemed non-exclusive, fully paid, royalty-free, perpetual and irrevocable. The ABSI Agreement would expire upon the expiration of the last Royalty Term of the last Product, unless such agreement is terminated earlier pursuant to its terms. The ABSI Agreement may also be terminated (i) by either the Company or ABSI for (A) a material breach of the ABSI Agreement or (B) bankruptcy, (ii) ABSI may terminate the ABSI Agreement upon the commencement of a Challenge Proceeding (as defined in the ABSI Agreement) or (iii) the Company may terminate the ABSI Agreement at any time upon 90 days prior written notice to ABSI. Upon termination or expiration of the ABSI Agreement other than as a result of a bankruptcy or Challenge Proceeding, all licenses granted to the Company pursuant to such agreement will terminate and all rights under such licenses would revert to ABSI.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 11, 2024, the Company entered into an addendum to the ABSI Agreement to fund research services with quarterly payments of $<span id="xdx_900_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20240311__20240311_zfZuHsgL6Bw9" title="Payments for research and development">50,000</span> beginning March 18, 2024 with subsequent payments due on the 18^th of each calendar quarter. Effective July 31, 2025, the quarterly services agreement was terminated. During the three and six months ended June 30, 2026 the Company incurred research service expense of $<span id="xdx_901_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20260401__20260630__us-gaap--TypeOfArrangementAxis__custom--AppliedBiomedicalScienceInstituteMember_z6hrOgYnZDNe" title="Payments for research and development"><span id="xdx_901_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20260101__20260630__us-gaap--TypeOfArrangementAxis__custom--AppliedBiomedicalScienceInstituteMember_z8hCFxtsrUd5" title="Payments for research and development">0</span></span> and during the three and six months ended June 30, 2025, the Company incurred research service expense of $<span id="xdx_904_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20250401__20250630__us-gaap--TypeOfArrangementAxis__custom--AppliedBiomedicalScienceInstituteMember_zFb8Se3WWH7c" title="Payments for research and development">50,000</span> and $<span id="xdx_904_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_c20250101__20250630__us-gaap--TypeOfArrangementAxis__custom--AppliedBiomedicalScienceInstituteMember_zDqoiUKqeKth" title="Payments for research and development">100,000</span>, respectively. Expenses related to the ABSI Agreement are included in continuing operations and the ABSI agreement is retained by the Company after the Gravitas Transaction (see Note 11).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Avior Patent License Agreement</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 3, 2023 (the “Avior Effective Date”), the Company entered into the Avior Patent License Agreement with Avior pursuant to which the Company received an exclusive sublicensable right and license to Licensed Patent Rights and Licensed Technology to, among other things, Develop, have Developed, make, have made, use, sell, import, export and commercialize GV104 and GV103 and to practice the Licensed Technology in connection with the foregoing, throughout the world. Pursuant to the Avior Patent License Agreement, the Company paid Avior an up front license fee of $<span id="xdx_90D_ecustom--UpfrontPayment_pn5n6_c20231103__20231103__us-gaap--TypeOfArrangementAxis__custom--IntractPatentLicenseAgreementMember_zJ1wO2Mc63d3" title="Upfront payment">0.4</span> million within ten days of the Avior Effective Date and a quarterly license fee of $<span id="xdx_902_ecustom--MilestoneFees_pn4n6_c20231103__20231103__us-gaap--TypeOfArrangementAxis__custom--IntractPatentLicenseAgreementMember_zdlKXg2ASI33" title="Milestone fees">0.15</span> million which was paid at the end of each fiscal quarter following the Avior Effective Date. In addition, the Company would pay Avior a high single digit percentage of any upfront payments received by it as a result of the grant of any sublicenses with respect to GV104. The Company would also pay Avior milestone payments in the aggregate amount of $<span id="xdx_90F_eus-gaap--PaymentsForOtherOperatingActivities_c20231103__20231103__srt--RangeAxis__srt--MaximumMember_zUAIbYJA7804" title="Payment of milestone amount">27,250,000</span> upon the occurrence of various development milestones (the “Development Milestone Payments”). Furthermore, the Company would pay Avior certain fees based upon sales milestones. The payments for such sales milestones range from the low seven digits to the low eight digits with higher sales being subject to higher fees. Finally, the Company would pay Avior royalties based on net sales. Such royalties range from low single digit percentages to mid-single digit percentages with higher sales being subject to lower percentages. The Avior Patent License Agreement would expire upon the expiration of the final payment obligation due to Avior as set forth in such agreement. Upon the expiration of the Avior Patent License Agreement, the Company would have a fully paid, irrevocable, freely transferable and sublicensable worldwide license to the Licensed Patent Rights and Licensed Technology to Develop, have Developed, make, have made, use, have used sell, offer for sale, have sold, import, have imported, export, have exported, commercialize or have commercialized any and all Licensed Products and to practice the Licensed Technology worldwide. Pursuant to the Avior Patent License Agreement, the Company may terminate the agreement at any time without cause, upon 30 days’ prior written notice to Avior along with payment of the next unpaid Development Milestone Payment, if any. Furthermore, either the Company or Avior may terminate the Avior Patent License Agreement (i) on written notice to the other party if the other party materially breaches any provision of the Avior Patent License Agreement and fails to cure such breach within 30 days after the breaching party receives written notice thereof or (ii) on written notice in the event that either party (A) becomes insolvent or admits its inability to pay its debts generally as they become due; (B) becomes subject, voluntarily or involuntarily, to any proceeding under any domestic or foreign bankruptcy or insolvency law, which is not fully dismissed or vacated within 60 days; (C) is dissolved or liquidated or takes any corporate action for such purpose; (D) makes a general assignment for the benefit of creditors; or (E) has a receiver, trustee, custodian or similar agent appointed by order of any court of competent jurisdiction to take charge of or sell any material portion of its property or business. Upon termination of the Avior Patent License Agreement, the license granted pursuant to such agreement shall terminate and all rights in the Licensed Patent Rights and Licensed Products shall revert back to Avior.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three and six months ended June 30, 2026, the Company incurred fees under the license agreement to Avior of $<span id="xdx_904_ecustom--MilestoneFees_c20260401__20260630__us-gaap--TypeOfArrangementAxis__custom--AviorPatentLicenseAgreementMember_zW8XgeKtXiHf" title="Milestone fees"><span id="xdx_907_ecustom--MilestoneFees_c20260101__20260630__us-gaap--TypeOfArrangementAxis__custom--AviorPatentLicenseAgreementMember_zyu8hIdb9Njf" title="Milestone fees">200,000</span></span>. During the three and six months ended June 30, 2025 the Company incurred fees under the license agreement to Avior of $<span id="xdx_901_ecustom--MilestoneFees_c20250401__20250630__us-gaap--TypeOfArrangementAxis__custom--AviorPatentLicenseAgreementMember_zwWUqkL8TMQb" title="Milestone fees">0</span> and $<span id="xdx_901_ecustom--MilestoneFees_c20250101__20250630__us-gaap--TypeOfArrangementAxis__custom--AviorPatentLicenseAgreementMember_zNS7Qa96OYU6" title="Milestone fees">200,000</span>, respectively. Fees incurred under the license agreement to Avior are reflected in discontinued operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Enkefalos License Agreement</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 17, 2024 (the “Enkefalos Effective Date”), the Company signed a letter of intent to enter into the Enkefalos License Agreement with Enkefalos Biosciences Inc. (“Enkefalos”) pursuant to which the Company is licensing the global rights in all fields of use for the products related to the compounds known as cyclotides to deliver HER2 antibodies across the blood-brain barrier and all associated know-how, technology, intellectual property and related information and constructs, and any associated authorized generic rights and all related assets (collectively, the “Products” referred to in this letter as ENBI-01) from Enkefalos. This agreement was terminated during the six months ended June 30, 2025. Pursuant to the Enkefalos License Agreement, the Company paid Enkefalos an up-front license fee of $<span id="xdx_904_ecustom--UpfrontPayment_c20240617__20240617__us-gaap--TypeOfArrangementAxis__custom--EnkefalosLicenseAgreementMember_zhNqXhhTf1G5" title="Upfront payment">150,000</span>, included within research and development expenses, within ten days of the Enkefalos Effective Date. Upon termination of the Enkefalos License Agreement, the license granted pursuant to such agreement terminated and all rights in the Licensed Patent Rights and Licensed Products reverted back to Enkefalos.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three and six months ended June 30, 2026 the Company incurred license fees of $<span id="xdx_90F_ecustom--LicenseFees_c20260401__20260630__us-gaap--TypeOfArrangementAxis__custom--EnkefalosLicenseAgreementMember_zQp4ji2VMJ9a" title="License fees"><span id="xdx_905_ecustom--LicenseFees_c20260101__20260630__us-gaap--TypeOfArrangementAxis__custom--EnkefalosLicenseAgreementMember_zUBl7fZ9WUKe" title="License fees">0</span></span> to Enkefalos in accordance with the terms of the agreement. During the three and six months ended June 30, 2025 the Company incurred license fees of $<span id="xdx_902_ecustom--LicenseFees_c20250401__20250630__us-gaap--TypeOfArrangementAxis__custom--EnkefalosLicenseAgreementMember_z7ruOXeskHJ1" title="License fees">0</span> and $<span id="xdx_906_ecustom--LicenseFees_c20250101__20250630__us-gaap--TypeOfArrangementAxis__custom--EnkefalosLicenseAgreementMember_zxsfI6VeWQi6" title="License fees">200,000</span>, respectively to Enkefalos in accordance with the terms of the agreement. Fees incurred under the license agreement to Enkefalos are reflected in discontinued operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Intract Patent License Agreement</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 11, 2024, the Company entered into the Intract Agreement pursuant to which the Company exclusively licensed INT-023/TH023, an oral anti-Tumor Necrosis Factor-alpha (TNF-α) monoclonal antibody infliximab. Under the terms of the Intract Agreement, the Company licensed global development and commercialization rights (outside of South Korea) to Intract’s Soteria® and Phloral® delivery platform along with an existing supply agreement for infliximab to be used in the oral product development program. Pursuant to the Intract Agreement, the Company paid Intract an up-front license fee of $<span id="xdx_90D_ecustom--UpfrontPayment_pn5n6_c20240911__20240911__us-gaap--TypeOfArrangementAxis__custom--IntractPatentLicenseAgreementMember_zubyoaofjaaa" title="Upfront payment">0.4</span> million and Intract is eligible to receive additional payments upon an equity financing of the Company and additional payments for future development, regulatory and commercial milestones, as well as mid-single digit royalties based on net product sales. During the six months ended June 30, 2025, the Company amended the Intract Agreement to change the payment terms of certain milestone fees, which increased the total milestone fees by $<span id="xdx_90C_ecustom--MilestoneFees_pn4n6_c20250101__20250630__us-gaap--TypeOfArrangementAxis__custom--IntractPatentLicenseAgreementMember_zoNwLhjkNf35" title="Milestone fees">0.15</span> million. Pursuant to the Intract Agreement, the Company retains a right of first refusal to continue development and commercialization after a Phase 2 clinical trial. In addition, the Company has the option to exercise the license to Intract’s platform for up to four additional targets. The term of the Intract Agreement expires upon the final payment obligation of Canton Strategic Holdings, Inc. and may be terminated by Canton Strategic Holdings, Inc. at any time upon 90 days written notice to Intract. Either party may terminate the Intract Agreement if the other party materially breaches any provision of the Intract Agreement and fails to cure such breach within 30 days after the breaching party receives written notice thereof. In addition, either party may terminate the Intract Agreement on written notice in the event that either party: (a) becomes insolvent or admits inability to pay its debts generally as they become due; (b) becomes subject, voluntarily or involuntarily, to any proceeding under any domestic or foreign bankruptcy or insolvency law, which is not fully dismissed or vacated within 60 days; (c) is dissolved or liquidated or takes any corporate action for such purpose; (d) makes a general assignment for the benefit of creditors; or (e) has a receiver, trustee, custodian or similar agent appointed by order of any court of competent jurisdiction to take charge of or sell any material portion of its property or business.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three and six months ended June 30, 2026 the Company incurred fees of $<span id="xdx_906_ecustom--LicenseFees_c20260401__20260630__us-gaap--TypeOfArrangementAxis__custom--IntractPatentLicenseAgreementMember_zTfPCug2VIlg" title="License fees"><span id="xdx_903_ecustom--LicenseFees_c20260101__20260630__us-gaap--TypeOfArrangementAxis__custom--IntractPatentLicenseAgreementMember_zoOHmvjKx9I7" title="License fees">0</span></span>, respectively to Intract in accordance with the terms of the agreement. During the three and six months ended June 30, 2025 the Company incurred fees of $<span id="xdx_907_ecustom--LicenseFees_c20250401__20250630__us-gaap--TypeOfArrangementAxis__custom--IntractPatentLicenseAgreementMember_zbIGSfZizpOe" title="License fees">0</span> and $<span id="xdx_90E_ecustom--LicenseFees_c20250101__20250630__us-gaap--TypeOfArrangementAxis__custom--IntractPatentLicenseAgreementMember_zEjZ7FOMz7I6" title="License fees">600,000</span>, respectively to Intract in accordance with the terms of the agreement. Fees incurred under the license agreement to Intract are reflected in discontinued operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 150000 1000000 0 0 0 0 25107 250000 10000000 8250000 50000 0 0 50000 100000 400000 150000 27250000 200000 200000 0 200000 150000 0 0 0 200000 400000 150000 0 0 0 600000 <p id="xdx_805_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zn4BkATNpz6k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 8 – <span id="xdx_82D_zNZ2BCEVpdq2">Related Party Transactions</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s Chairman through year ended December 31, 2025 is a partner and licensed broker at President Street Global, a consultant for the Company. His combined ownership, both individually and through President Street Global and additional companies, is approximately <span id="xdx_907_ecustom--InvestmentOwnershipPercentage_iI_pid_dp_uPure_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--PresidentStreetGlobalMember_zaMzhkNgQoSc" title="Investment ownership percentage">4</span>% of the Company’s outstanding common stock, including common shares available upon exercise of warrants and vested options to purchase shares of the Company’s common stock. The Company made payments of $<span id="xdx_90A_ecustom--DueToAffilatedRelatedParty_c20260401__20260630_z5FP8SDsdRz8" title="Affilate related party">150,000</span> and $<span id="xdx_90C_ecustom--DueToAffilatedRelatedParty_c20260101__20260630_z0aISdlMKlL4" title="Affilate related party">950,000</span> to President Street Global for services rendered during the three and six months ended June 30, 2026 respectively. $<span id="xdx_906_ecustom--DueToAffilatedRelatedParty_c20260401__20260630__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentDiscontinuedOperationsMember_z5qRSn5m6Jk6" title="Affilate related party">150,000</span> and $<span id="xdx_904_ecustom--DueToAffilatedRelatedParty_c20260101__20260630__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentDiscontinuedOperationsMember_zNlaVPNZTs9i" title="Affilate related party">450,000</span> of these payments are reflected in discontinued operations for the three and six months ended June 30, 2026, respectively. The Company made payments of $<span id="xdx_90E_ecustom--DueToAffilatedRelatedParty_c20250401__20250630_zeDYKvbDtOWg" title="Affilate related party">300,000</span> and $<span id="xdx_90C_ecustom--DueToAffilatedRelatedParty_c20250101__20250630_zPCjdFgJ6AEd" title="Affilate related party">700,000</span> to President Street Global for services rendered during the three and six months ended June 30, 2025 respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three and six months ended June 30, 2026, the Company purchased $<span id="xdx_901_ecustom--AffiliateExpenses_c20260401__20260630_zXiryLjnV426" title="Affiliate expense">1,982,705</span> and $<span id="xdx_907_ecustom--AffiliateExpenses_c20260101__20260630_zcuQkeR9slKd" title="Affiliate expense">49,205,003</span> of CC in OTC transactions from an affiliate cryptocurrency liquidity provider under the control of a shareholder who beneficially owns more than 5% of the Company’s outstanding common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0.04 150000 950000 150000 450000 300000 700000 1982705 49205003 <p id="xdx_80D_eus-gaap--SegmentReportingDisclosureTextBlock_zsexnZfqBjFh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 9 – <span id="xdx_826_zdiTB36XPaNj">Segment Reporting</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has <span id="xdx_90D_eus-gaap--NumberOfReportableSegments_dc_uSegment_c20260101__20260630_zv8pdYNf9ftc" title="Number of reportable segments">two</span> reportable segments: digital asset treasury and clinical stage bio-technology.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s Chief Executive Officer serves as the Chief Operating Decision Maker (“CODM”) and evaluates the financial performance of the business and makes resource allocation decisions on the basis of net income/(loss) before income taxes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zjlWhIDDg0Q2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Summary segment financial performance measures evaluated by the CODM as of June 30, 2026 and December 31, 2025 and for the three and six months ended June 30, 2026 and 2025:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BD_zY2h5EQT3PSj" style="display: none">Schedule of Segment Financial Performance</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom"> <td style="display: none"> </td><td style="display: none"> </td> <td colspan="2" id="xdx_496_20260630_zsgsnGMYDzHa" style="border-bottom: Black 1pt solid; display: none; text-align: center">June 30, 2026</td><td style="display: none"> </td><td style="display: none"> </td> <td colspan="2" id="xdx_49A_20251231_zu11MU9MFB7" style="border-bottom: Black 1pt solid; display: none; text-align: center">December 31, 2025</td><td style="display: none"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Segment Assets</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td> </td></tr> <tr id="xdx_40E_eus-gaap--Assets_iI_hus-gaap--StatementBusinessSegmentsAxis__custom--DigitalAssetTreasuryMember_zHZgl48jH8D" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Digital asset treasury segment</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">563,869,389</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">513,964,900</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--Assets_iI_hus-gaap--StatementBusinessSegmentsAxis__custom--ClinicalStageBioTechnologyMember__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_zkGdy8NqmwDb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Clinical stage bio-technology segment – continuing operations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1519">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1520">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--Assets_iI_hus-gaap--StatementBusinessSegmentsAxis__custom--ClinicalStageBioTechnologyMember__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentDiscontinuedOperationsMember_zkXSBmEbyoXf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Clinical stage bio-technology segment – held for sale</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">700,997</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5,181,535</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--Assets_iI_zaTl910o6kDa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total assets</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">564,570,386</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">519,146,435</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Digital asset treasury segment</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="display: none"> </td><td style="display: none"> </td> <td colspan="2" id="xdx_491_20260401__20260630__us-gaap--StatementBusinessSegmentsAxis__custom--DigitalAssetTreasuryMember_zOM2pWj1NQe1" style="border-bottom: Black 1pt solid; display: none; text-align: center">2026</td><td style="display: none"> </td><td style="display: none"> </td> <td colspan="2" id="xdx_494_20250401__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--DigitalAssetTreasuryMember_z9cDQL0qBgW7" style="border-bottom: Black 1pt solid; display: none; text-align: center">2025</td><td style="display: none"> </td><td style="display: none"> </td> <td colspan="2" id="xdx_497_20260101__20260630__us-gaap--StatementBusinessSegmentsAxis__custom--DigitalAssetTreasuryMember_zBuqJ749dLBj" style="border-bottom: Black 1pt solid; display: none; text-align: center">2026</td><td style="display: none"> </td><td style="display: none"> </td> <td colspan="2" id="xdx_492_20250101__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--DigitalAssetTreasuryMember_zvtrqB9F3gDf" style="border-bottom: Black 1pt solid; display: none; text-align: center">2025</td><td style="display: none"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the three months ended June 30,</td><td> </td><td> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the six months ended June 30,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td> </td></tr> <tr id="xdx_402_eus-gaap--OperatingIncomeLoss_zFPICUXSerUf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left">Loss from operations</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(1,202,154</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1529">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(36,423,335</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1531">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OtherNonoperatingIncomeExpense_zaJWEeDL9pD3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other income (expense) <span id="xdx_F4C_zNBJA5EZj2K9">(a)</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">311,848</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1534">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">630,026</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1536">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--CryptoAssetUnrealizedGainLossNonoperating_zKwfTWiE8Npa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Unrealized loss on digital assets holdings</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(23,735,950</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1539">-</span></td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(38,749,254</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1541">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_zt0FJcoXkGrb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total loss before income taxes</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(24,626,256</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1544">-</span></td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(74,542,563</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1546">-</span></td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Clinical stage bio-technology segment</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="display: none"> </td><td style="display: none"> </td> <td colspan="2" id="xdx_49A_20260401__20260630__us-gaap--StatementBusinessSegmentsAxis__custom--ClinicalStageBioTechnologyMember_zGxDTgPdR8gj" style="border-bottom: Black 1pt solid; display: none; text-align: center">2026</td><td style="display: none"> </td><td style="display: none"> </td> <td colspan="2" id="xdx_492_20250401__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--ClinicalStageBioTechnologyMember_zzxoUUhokhS" style="border-bottom: Black 1pt solid; display: none; text-align: center">2025</td><td style="display: none"> </td><td style="display: none"> </td> <td colspan="2" id="xdx_49B_20260101__20260630__us-gaap--StatementBusinessSegmentsAxis__custom--ClinicalStageBioTechnologyMember_zR39PfH7awc" style="border-bottom: Black 1pt solid; display: none; text-align: center">2026</td><td style="display: none"> </td><td style="display: none"> </td> <td colspan="2" id="xdx_491_20250101__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--ClinicalStageBioTechnologyMember_zeS3T1Th2c59" style="border-bottom: Black 1pt solid; display: none; text-align: center">2025</td><td style="display: none"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the three months ended June 30,</td><td> </td><td> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the six months ended June 30,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td> </td></tr> <tr id="xdx_40C_eus-gaap--OperatingIncomeLoss_hus-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_zQNWCKmiZuJb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left">Loss from operations – continuing operations</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1548">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(1,428,594</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1550">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(3,472,642</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--OperatingIncomeLoss_hus-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentDiscontinuedOperationsMember_zGS7FomNQl4k" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Loss from operations – discontinued operations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,300,745</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(422,566</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,947,875</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(925,187</td><td style="text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--OperatingIncomeLoss_hus-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentDiscontinuedOperationsMember_zj6U48Cgeboh" style="display: none; vertical-align: bottom; background-color: White"> <td style="display: none; text-align: left">Loss from operations</td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td style="display: none; text-align: right">(1,300,745</td><td style="display: none; text-align: left">)</td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td style="display: none; text-align: right">(422,566</td><td style="display: none; text-align: left">)</td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td style="display: none; text-align: right">(2,947,875</td><td style="display: none; text-align: left">)</td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td style="display: none; text-align: right">(925,187</td><td style="display: none; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--OtherNonoperatingIncomeExpense_zn2uTUIQwAhe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other income (expense) <span id="xdx_F4B_z0AX0akXpF5f">(a)</span></td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1563">-</span></td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(3,993</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1565">-</span></td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">972</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_zTNxsytns0Dd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total loss before income taxes</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,300,745</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,855,153</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,947,875</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4,396,857</td><td style="text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F07_z4nOvyXeeH8d" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F12_zmpsgCmqAxSd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other income (expense) consists of interest income and interest expense.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table is a reconciliation of segment total loss before income taxes to our consolidated total loss before income taxes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="display: none"> </td><td style="display: none"> </td> <td colspan="2" id="xdx_49B_20260401__20260630_zPZWQFyxfmQi" style="border-bottom: Black 1pt solid; display: none; text-align: center">2026</td><td style="display: none"> </td><td style="display: none"> </td> <td colspan="2" id="xdx_492_20250401__20250630_z58P0f6eBxPl" style="border-bottom: Black 1pt solid; display: none; text-align: center">2025</td><td style="display: none"> </td><td style="display: none"> </td> <td colspan="2" id="xdx_49B_20260101__20260630_zriiWQ2AZ6yh" style="border-bottom: Black 1pt solid; display: none; text-align: center">2026</td><td style="display: none"> </td><td style="display: none"> </td> <td colspan="2" id="xdx_492_20250101__20250630_zRP8jFFfLesg" style="border-bottom: Black 1pt solid; display: none; text-align: center">2025</td><td style="display: none"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the three months ended June 30,</td><td> </td><td> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the six months ended June 30,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td> </td></tr> <tr id="xdx_404_ecustom--IncomeLossFromContinuingAndDiscontinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_hus-gaap--StatementBusinessSegmentsAxis__custom--DigitalAssetTreasuryMember_zADyepMCGH92" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left">Digital asset treasury segment total loss before income taxes</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(24,626,256</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1575">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(74,542,563</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1577">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--IncomeLossFromContinuingAndDiscontinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_hus-gaap--StatementBusinessSegmentsAxis__custom--ClinicalStageBioTechnologyMember__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_zuFPIqYxOr25" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Clinical stage bio-technology segment total loss before income taxes – continuing operations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1579">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,432,587</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,471,670</td><td style="text-align: left">)</td></tr> <tr id="xdx_40F_ecustom--IncomeLossFromContinuingAndDiscontinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_hus-gaap--StatementBusinessSegmentsAxis__custom--ClinicalStageBioTechnologyMember__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentDiscontinuedOperationsMember_zzYHtLXqPse8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Clinical stage bio-technology segment total loss before income taxes – discontinued operations</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,300,745</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(422,566</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,947,875</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(925,187</td><td style="text-align: left">)</td></tr> <tr id="xdx_40F_ecustom--IncomeLossFromContinuingAndDiscontinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_zjdfYZwqYr4g" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Consolidated total loss before income taxes</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(25,927,001</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,855,153</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(77,490,438</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4,396,857</td><td style="text-align: left">)</td></tr> </table> <p id="xdx_8A2_zn5IgSToBxGc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 2 <p id="xdx_898_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zjlWhIDDg0Q2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Summary segment financial performance measures evaluated by the CODM as of June 30, 2026 and December 31, 2025 and for the three and six months ended June 30, 2026 and 2025:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BD_zY2h5EQT3PSj" style="display: none">Schedule of Segment Financial Performance</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom"> <td style="display: none"> </td><td style="display: none"> </td> <td colspan="2" id="xdx_496_20260630_zsgsnGMYDzHa" style="border-bottom: Black 1pt solid; display: none; text-align: center">June 30, 2026</td><td style="display: none"> </td><td style="display: none"> </td> <td colspan="2" id="xdx_49A_20251231_zu11MU9MFB7" style="border-bottom: Black 1pt solid; display: none; text-align: center">December 31, 2025</td><td style="display: none"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Segment Assets</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td> </td></tr> <tr id="xdx_40E_eus-gaap--Assets_iI_hus-gaap--StatementBusinessSegmentsAxis__custom--DigitalAssetTreasuryMember_zHZgl48jH8D" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Digital asset treasury segment</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">563,869,389</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">513,964,900</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--Assets_iI_hus-gaap--StatementBusinessSegmentsAxis__custom--ClinicalStageBioTechnologyMember__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_zkGdy8NqmwDb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Clinical stage bio-technology segment – continuing operations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1519">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1520">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--Assets_iI_hus-gaap--StatementBusinessSegmentsAxis__custom--ClinicalStageBioTechnologyMember__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentDiscontinuedOperationsMember_zkXSBmEbyoXf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Clinical stage bio-technology segment – held for sale</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">700,997</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5,181,535</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--Assets_iI_zaTl910o6kDa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total assets</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">564,570,386</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">519,146,435</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Digital asset treasury segment</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="display: none"> </td><td style="display: none"> </td> <td colspan="2" id="xdx_491_20260401__20260630__us-gaap--StatementBusinessSegmentsAxis__custom--DigitalAssetTreasuryMember_zOM2pWj1NQe1" style="border-bottom: Black 1pt solid; display: none; text-align: center">2026</td><td style="display: none"> </td><td style="display: none"> </td> <td colspan="2" id="xdx_494_20250401__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--DigitalAssetTreasuryMember_z9cDQL0qBgW7" style="border-bottom: Black 1pt solid; display: none; text-align: center">2025</td><td style="display: none"> </td><td style="display: none"> </td> <td colspan="2" id="xdx_497_20260101__20260630__us-gaap--StatementBusinessSegmentsAxis__custom--DigitalAssetTreasuryMember_zBuqJ749dLBj" style="border-bottom: Black 1pt solid; display: none; text-align: center">2026</td><td style="display: none"> </td><td style="display: none"> </td> <td colspan="2" id="xdx_492_20250101__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--DigitalAssetTreasuryMember_zvtrqB9F3gDf" style="border-bottom: Black 1pt solid; display: none; text-align: center">2025</td><td style="display: none"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the three months ended June 30,</td><td> </td><td> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the six months ended June 30,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td> </td></tr> <tr id="xdx_402_eus-gaap--OperatingIncomeLoss_zFPICUXSerUf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left">Loss from operations</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(1,202,154</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1529">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(36,423,335</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1531">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OtherNonoperatingIncomeExpense_zaJWEeDL9pD3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other income (expense) <span id="xdx_F4C_zNBJA5EZj2K9">(a)</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">311,848</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1534">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">630,026</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1536">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--CryptoAssetUnrealizedGainLossNonoperating_zKwfTWiE8Npa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Unrealized loss on digital assets holdings</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(23,735,950</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1539">-</span></td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(38,749,254</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1541">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_zt0FJcoXkGrb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total loss before income taxes</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(24,626,256</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1544">-</span></td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(74,542,563</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1546">-</span></td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Clinical stage bio-technology segment</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="display: none"> </td><td style="display: none"> </td> <td colspan="2" id="xdx_49A_20260401__20260630__us-gaap--StatementBusinessSegmentsAxis__custom--ClinicalStageBioTechnologyMember_zGxDTgPdR8gj" style="border-bottom: Black 1pt solid; display: none; text-align: center">2026</td><td style="display: none"> </td><td style="display: none"> </td> <td colspan="2" id="xdx_492_20250401__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--ClinicalStageBioTechnologyMember_zzxoUUhokhS" style="border-bottom: Black 1pt solid; display: none; text-align: center">2025</td><td style="display: none"> </td><td style="display: none"> </td> <td colspan="2" id="xdx_49B_20260101__20260630__us-gaap--StatementBusinessSegmentsAxis__custom--ClinicalStageBioTechnologyMember_zR39PfH7awc" style="border-bottom: Black 1pt solid; display: none; text-align: center">2026</td><td style="display: none"> </td><td style="display: none"> </td> <td colspan="2" id="xdx_491_20250101__20250630__us-gaap--StatementBusinessSegmentsAxis__custom--ClinicalStageBioTechnologyMember_zeS3T1Th2c59" style="border-bottom: Black 1pt solid; display: none; text-align: center">2025</td><td style="display: none"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the three months ended June 30,</td><td> </td><td> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the six months ended June 30,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td> </td></tr> <tr id="xdx_40C_eus-gaap--OperatingIncomeLoss_hus-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_zQNWCKmiZuJb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left">Loss from operations – continuing operations</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1548">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(1,428,594</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1550">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(3,472,642</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--OperatingIncomeLoss_hus-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentDiscontinuedOperationsMember_zGS7FomNQl4k" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Loss from operations – discontinued operations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,300,745</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(422,566</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,947,875</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(925,187</td><td style="text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--OperatingIncomeLoss_hus-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentDiscontinuedOperationsMember_zj6U48Cgeboh" style="display: none; vertical-align: bottom; background-color: White"> <td style="display: none; text-align: left">Loss from operations</td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td style="display: none; text-align: right">(1,300,745</td><td style="display: none; text-align: left">)</td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td style="display: none; text-align: right">(422,566</td><td style="display: none; text-align: left">)</td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td style="display: none; text-align: right">(2,947,875</td><td style="display: none; text-align: left">)</td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td style="display: none; text-align: right">(925,187</td><td style="display: none; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--OtherNonoperatingIncomeExpense_zn2uTUIQwAhe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other income (expense) <span id="xdx_F4B_z0AX0akXpF5f">(a)</span></td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1563">-</span></td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(3,993</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1565">-</span></td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">972</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_zTNxsytns0Dd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total loss before income taxes</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,300,745</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,855,153</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,947,875</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4,396,857</td><td style="text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F07_z4nOvyXeeH8d" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F12_zmpsgCmqAxSd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other income (expense) consists of interest income and interest expense.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table is a reconciliation of segment total loss before income taxes to our consolidated total loss before income taxes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="display: none"> </td><td style="display: none"> </td> <td colspan="2" id="xdx_49B_20260401__20260630_zPZWQFyxfmQi" style="border-bottom: Black 1pt solid; display: none; text-align: center">2026</td><td style="display: none"> </td><td style="display: none"> </td> <td colspan="2" id="xdx_492_20250401__20250630_z58P0f6eBxPl" style="border-bottom: Black 1pt solid; display: none; text-align: center">2025</td><td style="display: none"> </td><td style="display: none"> </td> <td colspan="2" id="xdx_49B_20260101__20260630_zriiWQ2AZ6yh" style="border-bottom: Black 1pt solid; display: none; text-align: center">2026</td><td style="display: none"> </td><td style="display: none"> </td> <td colspan="2" id="xdx_492_20250101__20250630_zRP8jFFfLesg" style="border-bottom: Black 1pt solid; display: none; text-align: center">2025</td><td style="display: none"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the three months ended June 30,</td><td> </td><td> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the six months ended June 30,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td> </td></tr> <tr id="xdx_404_ecustom--IncomeLossFromContinuingAndDiscontinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_hus-gaap--StatementBusinessSegmentsAxis__custom--DigitalAssetTreasuryMember_zADyepMCGH92" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left">Digital asset treasury segment total loss before income taxes</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(24,626,256</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1575">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(74,542,563</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1577">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--IncomeLossFromContinuingAndDiscontinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_hus-gaap--StatementBusinessSegmentsAxis__custom--ClinicalStageBioTechnologyMember__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentContinuingOperationsMember_zuFPIqYxOr25" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Clinical stage bio-technology segment total loss before income taxes – continuing operations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1579">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,432,587</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,471,670</td><td style="text-align: left">)</td></tr> <tr id="xdx_40F_ecustom--IncomeLossFromContinuingAndDiscontinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_hus-gaap--StatementBusinessSegmentsAxis__custom--ClinicalStageBioTechnologyMember__us-gaap--StatementOperatingActivitiesSegmentAxis__us-gaap--SegmentDiscontinuedOperationsMember_zzYHtLXqPse8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Clinical stage bio-technology segment total loss before income taxes – discontinued operations</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,300,745</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(422,566</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,947,875</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(925,187</td><td style="text-align: left">)</td></tr> <tr id="xdx_40F_ecustom--IncomeLossFromContinuingAndDiscontinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_zjdfYZwqYr4g" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Consolidated total loss before income taxes</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(25,927,001</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,855,153</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(77,490,438</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4,396,857</td><td style="text-align: left">)</td></tr> </table> 563869389 513964900 700997 5181535 564570386 519146435 -1202154 -36423335 311848 630026 -23735950 -38749254 -24626256 -74542563 -1428594 -3472642 -1300745 -422566 -2947875 -925187 -1300745 -422566 -2947875 -925187 -3993 972 -1300745 -1855153 -2947875 -4396857 -24626256 -74542563 -1432587 -3471670 -1300745 -422566 -2947875 -925187 -25927001 -1855153 -77490438 -4396857 <p id="xdx_802_eus-gaap--DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_zThx1nCPkUx5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 10 – <span id="xdx_82D_zW2HBxHmvs58">Discontinued Operations</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three months ended June 30, 2026, management committed to a plan for the divestiture of the Company’s wholly owned subsidiary, Gravitas. As of June 30, 2026, transaction documents were under negotiation with a buyer and in accordance with ASC 205-20, management concluded the held for sale criteria under ASC 360-10-45-9 were met and Gravitas is therefore reported as assets and liabilities held for sale and discontinued operations in the financial statements included herein. The Gravitas sale transaction closed on July 17, 2026 (see Note 11 – Subsequent Events for further details).</span></p> <p id="xdx_89D_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_zf3KOEMlvHs8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8BE_z7d21n8f42H2" style="display: none">Schedule of Discontinued Operations</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Summarized balance sheet information of assets and liabilities held for sale is below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_498_20260630_zXw20qCvDcr" style="text-align: center">June 30,</td><td> </td><td> </td> <td colspan="2" id="xdx_495_20251231_ztSqOWlTnBnb" style="text-align: center">December 31,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_406_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_iI_maAODGIzSFN_zbzWi6OJK4ra" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0pt; width: 64%; text-align: left">Cash and cash equivalents</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">576,806</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">5,025,600</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_iI_maAODGIzSFN_zUrDOQ849yJg" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0pt; text-align: left; padding-bottom: 1pt">Prepaid expenses and other current assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">124,191</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">155,935</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_iTI_mtAODGIzSFN_maAODGIzymF_zUucq2ixMfYh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Current assets held for sale</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">700,997</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5,181,535</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AssetsOfDisposalGroupIncludingDiscontinuedOperation_iTI_mtAODGIzymF_zfUwCo7zfQp" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Total assets held for sale</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">700,997</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,181,535</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_iI_maLODGIze6u_z003CYsZqOBi" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0pt; text-align: left">Accounts payable</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">235,566</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">569,073</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_iI_maLODGIze6u_z6zW2Y2BA7f4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0pt; text-align: left; padding-bottom: 1pt">Accrued expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">490,473</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,689,630</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_iTI_mtLODGIze6u_maLODGIzDpw_z5HFGx9RJlF6" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Total current liabilities held for sale</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">726,039</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,258,703</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_iTI_mtLODGIzDpw_zjqcOxKeIC3g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total liabilities held for sale</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">726,039</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,258,703</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The statement of operations of discontinued operations are summarized below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="display: none"> </td><td style="display: none; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20260401__20260630_zEqK9GLg8rt7" style="border-bottom: Black 1pt solid; display: none; text-align: center">2026</td><td style="display: none; padding-bottom: 1pt"> </td><td style="display: none; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20250401__20250630_zIZVCuDUWbl4" style="border-bottom: Black 1pt solid; display: none; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt"> </td><td style="display: none; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20260101__20260630_zT3rZLxIs1qc" style="border-bottom: Black 1pt solid; display: none; text-align: center">2026</td><td style="display: none; padding-bottom: 1pt"> </td><td style="display: none; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20250101__20250630_z9FfbsJn50Sk" style="border-bottom: Black 1pt solid; display: none; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the Three Months Ended June 30,</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the Six Months Ended June 30,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_404_ecustom--DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment_maDGIDOzznj_zWnad3EJ7chl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 44%; text-align: left">Research and development</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">411,767</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">422,566</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">679,590</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">925,187</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_maDGIDOzznj_z5lc7ccIaPp7" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">888,978</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1628">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,268,285</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1630">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOperatingExpense_iT_mtDGIDOzznj_msILFDOzJRl_z7elec1PES19" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Total operating expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,300,745</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">422,566</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,947,875</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">925,187</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTax_iT_mtILFDOzJRl_za9ta8nfc2X3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Net loss from discontinued operations</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,300,745</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(422,566</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,947,875</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(925,187</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> </table> <p id="xdx_8A2_ztXAxSRJrTC6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89D_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_zf3KOEMlvHs8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8BE_z7d21n8f42H2" style="display: none">Schedule of Discontinued Operations</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Summarized balance sheet information of assets and liabilities held for sale is below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_498_20260630_zXw20qCvDcr" style="text-align: center">June 30,</td><td> </td><td> </td> <td colspan="2" id="xdx_495_20251231_ztSqOWlTnBnb" style="text-align: center">December 31,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_406_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_iI_maAODGIzSFN_zbzWi6OJK4ra" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0pt; width: 64%; text-align: left">Cash and cash equivalents</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">576,806</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">5,025,600</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_iI_maAODGIzSFN_zUrDOQ849yJg" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0pt; text-align: left; padding-bottom: 1pt">Prepaid expenses and other current assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">124,191</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">155,935</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_iTI_mtAODGIzSFN_maAODGIzymF_zUucq2ixMfYh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Current assets held for sale</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">700,997</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5,181,535</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AssetsOfDisposalGroupIncludingDiscontinuedOperation_iTI_mtAODGIzymF_zfUwCo7zfQp" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Total assets held for sale</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">700,997</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,181,535</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_iI_maLODGIze6u_z003CYsZqOBi" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0pt; text-align: left">Accounts payable</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">235,566</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">569,073</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_iI_maLODGIze6u_z6zW2Y2BA7f4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0pt; text-align: left; padding-bottom: 1pt">Accrued expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">490,473</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,689,630</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_iTI_mtLODGIze6u_maLODGIzDpw_z5HFGx9RJlF6" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Total current liabilities held for sale</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">726,039</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,258,703</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_iTI_mtLODGIzDpw_zjqcOxKeIC3g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total liabilities held for sale</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">726,039</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,258,703</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The statement of operations of discontinued operations are summarized below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="display: none"> </td><td style="display: none; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20260401__20260630_zEqK9GLg8rt7" style="border-bottom: Black 1pt solid; display: none; text-align: center">2026</td><td style="display: none; padding-bottom: 1pt"> </td><td style="display: none; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20250401__20250630_zIZVCuDUWbl4" style="border-bottom: Black 1pt solid; display: none; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt"> </td><td style="display: none; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20260101__20260630_zT3rZLxIs1qc" style="border-bottom: Black 1pt solid; display: none; text-align: center">2026</td><td style="display: none; padding-bottom: 1pt"> </td><td style="display: none; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20250101__20250630_z9FfbsJn50Sk" style="border-bottom: Black 1pt solid; display: none; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the Three Months Ended June 30,</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">For the Six Months Ended June 30,</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_404_ecustom--DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment_maDGIDOzznj_zWnad3EJ7chl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 44%; text-align: left">Research and development</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">411,767</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">422,566</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">679,590</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">925,187</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_maDGIDOzznj_z5lc7ccIaPp7" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">888,978</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1628">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,268,285</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1630">-</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOperatingExpense_iT_mtDGIDOzznj_msILFDOzJRl_z7elec1PES19" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Total operating expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,300,745</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">422,566</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,947,875</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">925,187</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTax_iT_mtILFDOzJRl_za9ta8nfc2X3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Net loss from discontinued operations</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,300,745</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(422,566</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,947,875</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(925,187</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> </table> 576806 5025600 124191 155935 700997 5181535 700997 5181535 235566 569073 490473 1689630 726039 2258703 726039 2258703 411767 422566 679590 925187 888978 2268285 1300745 422566 2947875 925187 -1300745 -422566 -2947875 -925187 <p id="xdx_809_eus-gaap--SubsequentEventsTextBlock_zcAPwg8fSFC8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 11 – <span id="xdx_820_zmXtCRqfd5Tj">Subsequent Events</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except as noted below, there were no material subsequent events that required recognition or additional disclosure in these consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Sale of Gravitas</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 17, 2026, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Gravitas Collective Corp., a Delaware corporation (“Buyer”), pursuant to which the Company agreed to sell, and Buyer agreed to purchase, all of the issued and outstanding membership interests (the “Purchased Securities”) of Gravitas, (the “Gravitas Transaction”). In connection with the Gravitas Transaction, Gravitas was converted from a Delaware corporation into a Delaware limited liability company on July 16, 2026. Gravitas operates clinical-stage biotech research and development that develops therapeutic candidates for immunology and inflammation conditions. The Buyer is affiliated with Vincent LoPriore, Sireesh Appajosyula and Gary Stetz, former directors of the Company. In connection with the Gravitas Transaction, the Board of Directors has formed a special committee, consisting of independent non-interested directors to review the terms of the Gravitas Transaction to ensure it is in the best interests of the Company’s stockholders. On July 15, 2026, the Gravitas Transaction was approved by the special committee and, upon the recommendation of the special committee, the full Board of Directors voted to approve the Gravitas Transaction.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As consideration for the Purchased Securities, Buyer and Gravitas issued to the Company an unsecured promissory note in the original principal amount of $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_c20260717__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--UnsecuredPromissoryNoteMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zBh2xTBoYjt7" title="Principal amount">3,500,000</span> (the “Gravitas Note”) and agreed to pay to the Company certain development milestone payments in the event such payments become due and payable. The Gravitas Note bears interest at a rate of <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20260717__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--DebtInstrumentAxis__custom--UnsecuredPromissoryNoteMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zIumS0O7m2Sj" title="Interest rate">15</span>% per annum, payable in kind and compounding semi-annually, with accrued interest added to the outstanding principal balance. The Gravitas Note contains mandatory prepayment and optional prepayment mechanisms, and a maturity date of July 17, 2029. Concurrently with the execution of the Purchase Agreement, the Company also entered into release agreements with certain individuals in connection with the Gravitas Transaction. Certain assets of Gravitas relating to bispecific antibodies development (the “Oncology Program”) were retained by the Company through its subsidiary Tharimmune SPV1 LLC, pursuant to a Bill of Sale, Assignment and Assumption Agreement entered into in connection with the Gravitas Transaction. The Oncology Program assets do not have any book value and therefore are not material to the Company. The Company is evaluating next steps with regard to these assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Transaction was completed on July 17, 2026.</span></p> 3500000 0.15 false false false false The exercise and expiration dates for the referenced common warrants were amended in October 2025 to reflect an exercise date of October 1, 2025. Other income (expense) consists of interest income and interest expense.